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Introduction
Due to the rapidly aging population dementia is increasingly becoming a large 
problem in Western society. Worldwide approximately 25 million people suffer 
from dementia and this number is thought to increase to more than 80 million 
in 2040.1 Furthermore, dementia is one of the main causes of disability in later 
life; in terms of Global Burden of Disease, it contributes 11.2% of all years lived 
with disability, which is higher than stroke (9.5%), musculoskeletal disorders 
(8.9%), heart disease (5%) and cancer (2.4%).2 In addition to the devastating 
effects on patients and their families, dementia also results in a high economical 
burden on the society. In 2005 3.2 billion euro, 4.7% of the total of 68.5 billion 
euro spent on healthcare and related welfare costs in the Netherlands was related 
to dementia and these figures will rise further with increasing prevalence.3
Clinically, dementia is defined as an acquired decline of memory and other 
cognitive domains that affect social and occupational functioning but also 
includes symptoms like language difficulties, problems with judgment and insight, 
disorientation, mood changes, hallucinations and delusions. At the moment 
there is no effective treatment for this disease and treatment mostly concentrates 
on improvement of the quality-of-life and environmental modifications.4 The 
diagnosis of dementia requires a medical history, physical and neurological 
examination, neuropsychological testing and appropriate laboratory tests with 
the mainstay of the diagnosis being the development of consensus clinical 
diagnostic criteria, which now exist.5-8 However, for the definitive diagnosis of 
the pathology underlying a dementia syndrome, histopathological information 
(in general acquired at autopsy) is still required.6
Alzheimer type pathology and vascular pathology, traditionally presumed 
to be responsible for Alzheimer’s disease (AD) and vascular dementia (VaD) 
respectively, are considered the most important histopathological correlates for 
dementia.9 Alzheimer pathology is characterized by extracellular amyloid plaques 
and intracellular neurofibrillary tangles whereas vascular pathology exerts its 
detrimental effect through infarction, chronic hypoperfusion and intracranial 
hemorrhage. However, when patients come to autopsy only few patients can 
be diagnosed with “pure” AD or “pure” vascular dementia.9 In addition, other 
pathological processes like inflammation10, previous head trauma11 but also 
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genetic12 and environmental factors13 are increasingly recognized as contributing 
to the dementia process. Therefore, dementia is more and more considered to 
be a multi-factorial process in which different pathological mechanisms interact. 
An excellent tool for untangling these pathological processes underlying 
dementia is Magnetic Resonance Imaging (MRI). MRI is an imaging technique 
that allows the imaging of pathological processes in the brain. The technique 
is non-invasive and can be used in-vivo and is therefore able to depict 
neuropathology in the brain before the patient comes to autopsy. Furthermore, 
MRI offers the opportunity of multiple analyses during an evolving disease 
process or even before clinical symptoms become apparent. From early on MRI 
applied to dementia and the cerebral aging process mainly focused on atrophy, 
the hallmark of AD, and markers of cerebrovascular disease.14;15 These studies 
showed that in the aging brain annual atrophy16 can be expected at small rates 
whereas accelerated parenchyma loss of specific brain regions can be found in 
various neurodegenerative diseases.17-19 White matter lesions20 and stroke21 
were shown to be independently associated with cognitive dysfunction but also 
interact with other pathologies to lower the threshold for dementia.22
Parallel to the increasing recognition of dementia being a multi-factorial process, 
new MRI markers of cerebral aging with potential clinical consequences have 
emerged. For example, cerebral microbleeds received much attention in the light 
of cerebral hemorrhage although their prevalence, risk factors, and potential 
functional consequences in the aging population are only recently under 
investigation.23 Furthermore, the accumulation of iron24 and other minerals25 in 
the brain is known in various neurodegenerative diseases but data of their role 
in the cerebral aging process is still scarce. In addition, MRI correlates have been 
found for newly recognized potential risk factors for dementia like hypertension26, 
obesity27, diabetes mellitus28 but also depression29 and level of education30. These 
findings all point to new pathways underlying cognitive decline. 
Another process that is contributing significantly to the increasing insight of 
the cerebral aging process is the development of so-called “quantitative” MRI 
techniques, such as diffusion-weighted imaging (DWI), magnetization transfer 
imaging (MTI) and MR spectroscopy. These techniques have provided new 
MRI-parameters that are particularly sensitive for ultra-structural changes 
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in the brain parenchyma, potentially even before clinical symptoms become 
apparent. This is particularly important in the light of the increasing recognition 
of conditions that may precede dementia, such as mild cognitive impairment 
(MCI). Furthermore, these quantitative techniques might also play a role in 
differentiating pathologic from normal aging in the early stages of disease. 
This points to an essential issue in the study of the processes underlying cognitive 
decline: it should be realized that for the appreciation of findings in dementia, 
especially in these early stages of disease, it is of paramount importance to 
differentiate normal age-related brain variations from the effects of these 
neurodegenerative processes. Not only does the lesion load of age-related changes 
in the brain vary strongly between subjects in the aging population, but also 
the functional consequences of these lesions are unpredictable. This can make 
normal aging and neurodegenerative disease hard to distinguish when lacking 
knowledge of the cerebral aging process. Therefore, investigation of the cerebral 
aging process is almost obligatory for the full understanding of dementia.
The general aim of this thesis was to investigate emerging (quantitative) MR 
techniques and potential new MRI markers of cognitive decline in both normal 
aging and AD. 
One of these quantitative MR techniques is magnetization transfer imaging, a 
quantitative MR technique based on the interaction between free water protons 
and protons with restricted mobility (e.g.: in the macromolecules of myelin and 
other cell membranes). MTI has been shown to be sensitive to structural changes 
in both white matter and gray matter in various neurological diseases. In chapter 
2 we apply this technique to investigate structural changes in the gray and white 
matter of AD and MCI patients. With increasing evidence for an important role 
of vascular pathology in the development of AD even in the early stages of the 
disease, we hypothesize that MTI changes could be detected in both gray and 
white matter. 
In chapter 3 we investigate how these MTI changes in gray and white matter 
found in chapter 2 are distributed over the brain in MCI and AD patients. It 
is assumed that MTI changes related to classical AD pathology originate from 
the temporal gray matter whereas vascular pathology, mainly reflected in white 
matter MTI changes, would have a more diffuse distribution. 
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12
Measurement of cerebral blood flow is a technique that could contribute to the 
investigation of the possible vascular pathology underlying age related changes 
of the brain as it allows us to quantify the cerebral blood flow. In chapter 4 
we investigate whether the total cerebral blood flow is related to white matter 
hyperintensity volume and cerebral atrophy. Furthermore, we investigate 
whether these associations are influenced by correcting total cerebral blood flow 
for brain volume.
Another technique that is closely related to the measurement of the cerebral 
blood flow is the measurement of wall shear stress. Wall shear stress (WSS) is 
the frictional force exerted by the circulating blood on the arterial intima and is 
thought to reflect the overall state of a vessel as it is correlated with the presence 
and progression of atherosclerosis. Low WSS has been associated with aging, 
gender and various cardiovascular risk factors. As mentioned earlier, vascular 
pathology is increasingly seen as a factor contributing to the development of AD 
and with this in mind we hypothesize that lower WSS parameters could be found 
in patients suffering from MCI or AD. This study is described in chapter 5.
Microbleeds are peri-vascular deposits of blood breakdown products, mainly 
haemosiderin. Histopathologically, these lesions have been associated with 
hypertensive vasculopathology and cerebral amyloid angiopathy. Although 
these lesions have been intensively studied in the light of both hemorrhagic 
and ischemic stroke, less is known regarding their risk factors and associations 
with other MRI markers of neurodegeneration in the general population. This 
is mainly attributable to the low prevalence of microbleeds in this population. 
The purpose of the study described in chapter 6 is to define the cardiovascular 
risk factors for microbleeds and to investigate associations between microbleeds 
and radiological signs of neurodegeneration. The chosen study population 
comprised patients suffering from cardiovascular disease or at high risk for 
developing this condition and allowed us to investigate these questions without 
the type-II errors encountered in previous studies. 
In addition to risk factors and associations with other markers of 
neurodegeneration, the potential influence of microbleeds on cognition is 
studied in chapter 7. In this study the association was assessed between the 
presence and location of the microbleeds on the one hand, and on the other 
hand performance on a large battery of cognitive tests.
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An age related increase in basal ganglia hypo-intensity on T2-weighted MR 
imaging, attributed to increasing iron concentrations, has been found in 
previous studies. Furthermore, this phenomenon has been associated with 
a number of neurological diseases including AD, Parkinson’s, Huntington’s 
disease and multiple sclerosis. In chapter 8 we present a new rating scale that was 
developed to provide a qualitative analysis of the basal ganglia intensity on T2*-
weighted images, an MRI sequence particularly sensitive to the dephasing effect 
of iron. This semi-quantitative score is then associated with known markers of 
neurodegeneration in the aging population.
In chapter 9 a method for automated detection and classification of hypo-
intense regions on T2-weighted MR images of the basal ganglia is introduced. 
The volumes of basal ganglia hypo-intensity rendered by this method are 
associated with parameters of cognitive functioning. Furthermore, risk factors 
for increasing basal ganglia hypo-intensity volume are investigated. 
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Abstract
Objective
To assess whether structural brain damage as detected by magnetization transfer 
imaging (MTI) in Alzheimer’s disease (AD) and mild cognitive impairment 
(MCI) is located in the gray matter (GM) and/or the white matter (WM).
Methods 
Fifty-five AD patients, 19 MCI patients and 43 subjects with normal cognitive 
function participated in this study. GM and WM segmentations were generated 
from dual fast spin-echo MR images. These masks were co-registrated to MT 
images for volumetric MTI analysis of the GM and WM.
Results
AD patients had a lower GM volume than controls. Both MCI and AD patients 
had more structural brain damage in both GM and WM than subjects with 
normal cognition. Cerebral lesion load in both GM and WM was associated with 
the degree of cognitive impairment.
Conclusion
Using MTI, structural brain changes that are related to cognitive impairment 
could be demonstrated in both GM and WM of patients with AD and MCI. 
These results suggest that cerebral changes are present in GM and WM even 
before patients are clinically demented.
Magnetization Transfer Imaging in MCI and AD
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Introduction
There is a growing body of evidence that in addition to the classical ‘Alzheimer-
type’ neuropathology of senile plaques and neurofibrillary tangles, vascular 
pathology also plays a role in the neurodegenerative processes leading to the 
clinical syndrome of Alzheimer’s disease (AD).9;22;31 On magnetic resonance 
imaging (MRI), Alzheimer-type pathology is associated with changes in 
gray matter (GM), whereas vascular pathology mostly occurs in white matter 
(WM).32-36 Abnormalities in the GM and WM often coexist and may even 
interact in AD.37-39 
Magnetization transfer imaging (MTI) is a quantitative MR technique that 
can be used to assess the load of structural brain changes in vivo.40;41 Using 
MTI widespread brain changes were demonstrated in AD. 42-44 Moreover, 
these widespread changes were also observed in patients with mild cognitive 
impairment (MCI).44 A preliminary study suggested that these changes are largely 
attributable to GM changes.43 However, this study was done in small patient 
and control groups. In addition, mean magnetization transfer ratio (MTR) 
was used as the sole outcome measure for MTI analysis, whereas histogram 
peak height proved to be a more sensitive MTI parameter for detecting brain 
pathology in various diseases.42;45;46 Hence, it remains largely unknown whether 
the widespread damage detected by MTI in AD and MCI is located uniquely in 
GM. With accumulating evidence for an important role of vascular pathology 
in the development of AD, it could be hypothesized that abnormalities occur in 
both the GM and WM. 
Therefore, in the present study, we investigated whether the previously found 
structural brain damage detected by MTI in AD and MCI is located in the GM 
and/or in the WM of the brain in patients with MCI and AD.
Methods
Patients
Elderly subjects that were consecutively referred to our outpatient memory 
clinic participated in this study. Fifty-five patients with probable AD, 19 patients 
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with MCI and 43 subjects with normal cognitive function were included. The 
normal group included 19 patients who were evaluated for memory complaints, 
but who had no detectable cognitive deficits on neuropsychological testing, 
and 24 volunteers without memory complaints who were recruited through 
an advertisement in a local newspaper. All subjects were evaluated for memory 
complaints using a standardized dementia screening that included a detailed 
medical history, a general internal and neurological exam, laboratory tests, 
neuropsychological testing including the Mini Mental State Examination 
(MMSE)47 and MRI of the brain. Diagnoses were made in a multidisciplinary 
consensus meeting according to the National Institute of Neurological and 
Communicative Disorders and Stroke–Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA) criteria for probable AD and the 
criteria according to Petersen for MCI.6;48;49 The following criteria were used 
to diagnose MCI: (1) memory complaint; (2) impaired memory function on 
cognitive testing; (3) preserved general cognitive functioning; (4) intact activities 
of daily living; (5) not demented. Patients and controls were included if they: 
(1) were older than 60 years; (2) had no other neurologic or psychiatric illness; 
and (3) had no abnormalities on MRI other than white matter hyperintensities 
or an incidental small lacunar lesion (≤ 5 mm diameter). The study was approved 
by the local Medical Ethical Committee. Written informed consent was obtained 
from all subjects or from a close relative if a patient was demented.
MRI data
MRI was performed on a 1.5 T MR system (Philips Medical Systems, Best, The 
Netherlands). Conventional dual fast spin-echo sequences [48 axial slices; slice 
thickness= 3 mm; no gap; TR/TE (ms) 3000/27/120; flip angle = 90°; field 
of view = 220 mm; matrix 256 x 256] were obtained in all patients. The line 
through the inferior border of the genu and splenium of the corpus callosum 
defined the direction of scanning. MTI of the brain was performed using a three 
dimensional (3D) gradient-echo pulse sequence [28 axial slices, slice thickness 
= 5 mm; no gap; repetition time/echo time (ms) 106/6; flip angle = 12°; field 
of view = 220 mm; matrix = 256 x 256, a sinc-shaped saturation pulse 1100 Hz 
below the frequency of water was added].50 These scan parameters were chosen 
to minimize T1 and T2 weighting, resulting in a proton-density contrast in the 
absence of MT saturation pulses. Two consecutive sets of images were acquired; 
the first was performed in combination with the MT saturation pulse, and the 
second without. The total scan time was 29 min and 22 s.
Magnetization Transfer Imaging in MCI and AD
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Image post-processing
Images were analysed using Software for Neuro-Image Processing in Experimental 
Research (SNIPER), an in-house developed program for image processing.51 
Briefly, the post-processing included the following steps (Fig. 2.1). First, the 
proton-density (PD) image is used to create an intracranial mask. Subsequently, 
the PD and T2 images are combined to generate segmentations of GM and WM. 
Third, a custom template is applied to exclude the cerebellum, brainstem and 
basal ganglia from analysis. Atrophy measures for whole brain, GM and WM 
are generated. Atrophy is defined as parenchyma volume divided by intracranial 
volume. Finally, these masks are co-registered to the MT images. The MTR for 
each voxel within the mask of whole brain, GM and WM respectively is calculated 
automatically using the formula MTR = ((M0 − Ms) / M0) x 100%, in which Ms 
represents the signal intensity of voxels with saturation and M0 represents the 
intensity of voxels without saturation. In the resulting MTR map, voxel values 
represent the percentage of signal loss caused by transfer of magnetization of the 
saturated immobile macromolecular-bound to the free water pool of protons.50 
The frequency distributions of MTR values were displayed as MTR histograms 
of whole brain, GM and WM, respectively.50 From each histogram, the mean 
MTR and the peak height − two measures reflecting structural brain damage 
– were derived. The peak height was normalized for brain size by dividing the 
number of voxels on the peak by the total number of segmented voxels. The 
normalized peak height thus obtained is a measure reflecting the amount of 
remaining normal brain tissue, independent of brain size and atrophy.46 
Figure 2.1. Automatic segmentation process. Intracranial segmentation (A); gray 
matter and white matter segmentation (B); mask co-registered to MTI image (C).
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Statistical analysis
SPSS for Windows (release 10.0; SPSS, Chicago, IL) was used for data analysis. 
The volumetric measurements of whole brain, GM and WM were corrected for 
head size by dividing them by intracranial volume. Categorical variables were 
analyzed using a Chi-square test. Differences in group means were analyzed 
using analysis of variance (ANOVA) with post hoc Bonferroni tests. Pearson 
correlation analysis was used to investigate associations between the MTI 
parameters and cognition as expressed by the MMSE. The level of statistical 
significance was set at p < 0.05.
Results
There were no differences in sex, age or education between groups (Table 2.1). 
As expected, AD patients had a lower MMSE score than MCI patients and 
subjects with normal cognition.
Table 2.2 shows atrophy of the whole brain, GM and WM by diagnostic group. 
Patients with AD showed more atrophy than subjects with normal cognition. 
When we inspected GM and WM separately, this difference could largely be 
attributed to significantly more GM atrophy. There was no significant difference 
in whole brain, GM or WM atrophy between patients with MCI and any of the 
other groups. 
Table 2.1 Demographic and clinical characteristics.
Normal Cognition MCI AD
Sex (m/f)a 15/28 5/14 28/27
Age (yr) 73 (7) 77 (6) 74 (8)
Education (yr) 11 (4) 10 (4) 10 (4)
MMSE 28 (2) 26 (1)  18 (5)*
Data are represented as mean (± SD) 
MCI = Mild Cognitive Impairment, AD = Alzheimer’s Disease, MMSE = Mini Mental 
State Examination.
a Chi-Square test
* = Differs from group with normal cognition and MCI (p < 0.001)
Magnetization Transfer Imaging in MCI and AD
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The peak height of the whole brain MTR histogram was reduced in patients 
with MCI and AD compared to subjects with normal cognition (Table 2.3). No 
differences were found between MCI and AD patients. In addition, AD patients 
had a lower whole brain mean MTR than controls. MCI patients differed 
Table 2.2 Atrophy.
Normal Cognition MCI AD
Whole Brain (%) 74.7 (4.2) 72.5 (5.6) 71.2 (5.1)*
Gray Matter (%) 43.2 (3.4) 41.1 (3.7) 40.6 (4.0)*
White Matter (%) 31.5 (4.2) 31.4 (5.8) 30.7 (4.6)
 
Data are represented as mean (± SD)
MCI = Mild Cognitive Impairment, AD = Alzheimer’s Disease
Atrophy is defined as parenchyma volume divided by intracranial volume. Therefore, 
the numbers represents the % of intracranial volume occupied by brain parenchyma 
* = Differs from group with normal cognition (p < 0.01) 
Table 2.3 MTR measures of whole brain, gray matter and white matter.
Normal Cognition MCI AD
Whole Brain peak height 97.3 (12.5) 83.9 (13.2)* 80.2 (10.9)*
mean MTR 30.8 (1.1) 30.4 (1.0) 29.8 (1.1)*
Gray Matter peak height 68.4 (11.7) 57.2 (10.8)* 51.9 (7.7)*
mean MTR 28.0 (1.5) 27.3 (1.4) 26.5 (1.5)*
White Matter peak height 144.3 (17.5) 124.3 (21.7)* 122.3 (18.8)*
mean MTR 34.7 (0.9) 34.4 (1.2) 34.2 (1.0)
Data are represented as mean (± SD)
MCI = Mild Cognitive Impairment, AD = Alzheimer’s Disease
The peak height was normalized for volume (number of voxels on the peak divided by 
the total number of segmented voxels)
* = Differs from group with normal cognition (p < 0.01) 
Chapter 2
22
Figure 2.2. Mean peak heights of gray matter (A) and white matter (B) in the three 
groups. Error bars represent standard error. 
* = Differs from group with normal cognition (p < 0.01).
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neither from AD patients nor controls. The observed structural changes in the 
whole brain were attributable to changes in both GM and WM, as MCI and AD 
patients showed a reduced peak height in the histograms of both GM and WM 
(Fig. 2.2). There were no significant differences between MCI and AD patients. 
AD patients had a lower mean MTR of the GM than controls, but not of the 
WM. No significant difference was found for GM or WM mean MTR between 
MCI patients on the one hand and AD patients or controls on the other. 
Across subjects, there were significant associations between both GM (Fig. 2.3a) 
and WM (Fig. 2.3b) peak height and MMSE score (GM: r = 0.53, WM: r = 0.41, 
p < 0.001). In addition, mean MTR of the GM was associated with MMSE score 
(r = 0.37, p < 0.001), but there were no significant correlations between mean 
MTR of the WM and MMSE score. There was a weak association between GM 
atrophy and MMSE score (r = 0.21, p = 0.02). WM atrophy was not associated 
with MMSE score.
Discussion
In this study using MTI, structural brain changes that were related to cognitive 
impairment were shown in both the GM and WM of patients with MCI and AD. 
In contrast, atrophy was only observed in the GM of AD patients. Patients with 
MCI did not show evidence of atrophy in either GM or WM. 
Neuropathologically, AD is characterized by the accumulation of extracellular 
amyloid plaques and intracellular neurofibrillary tangles in the GM.32 Vascular 
pathology, that may primarily lead to WM damage, is increasingly recognized as 
a second causative factor underlying the development of the clinical syndrome 
of AD.9;22;31;33;36;52 Alzheimer-type pathology and vascular pathology have been 
shown to be the two major correlates of cognitive decline at old age, with no 
clear thresholds predicting dementia.9 It has been hypothesized that both types 
of pathology add up, until a threshold is reached and the clinical syndrome of 
AD becomes apparent.22 MRI-studies have confirmed in vivo that damage to 
the GM and WM often coexists in dementia.37-39;53 In the present study, we were 
able to extend these findings as the current studies support the possibility that 
structural damage is present in the GM and in the WM of MCI patients, that 
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Figure 2.3. Scatterplots of MMSE versus gray matter (A) and white matter (B) peak 
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are not yet demented. There is one earlier study using MTI of GM and WM in 
patients with MCI. Contrasting with the present study, this small study observed 
only structural changes in the GM of patients with MCI. In line with our findings 
however, a recent study using DTI observed ultrastructural changes in both the 
GM and WM of MCI patients.54
Although the WM changes as observed with MTI may be of vascular origin9;22;31, 
the sole attribution of WM changes found with MTI to vascular pathology is 
somewhat tentative. It has even been postulated that myeline breakdown is the 
primary process leading to AD.55;56 In this model, an age related progressive 
pattern of myeline breakdown that recapitulates the developmental process 
of myelination in reverse leads to neuronal “disconnections”. Homeostatic 
responses to this myeline breakdown increase intracortical toxicity and might 
explain the non-random progressive neuronal damage of AD. It could very well 
be that this process contributed to the WM pathology found in our study. In 
addition, it could be argued that the WM damage observed in AD and MCI 
patients reflects Wallerian degeneration resulting of neuronal degeneration in 
the cortex, rather than vascular pathology. However, if Wallerian degeneration 
would be the underlying cause of the observed MTR changes, one would expect 
atrophy of the WM to co-occur. Evidence for WM atrophy has not been found 
in this study. 
MTI is one of the so-called quantitative MR-techniques, i.e. highly sensitive to 
structural brain changes.40;41 Changes in tissue structure in the absence of volume 
changes that are apparent on conventional MR, could be demonstrated in several 
diseases.40;43;44;46;57 Although MTI has been developed to study WM changes in 
multiple sclerosis, it is also sensitive to changes in tissue structure of the GM.43;58-
60 This makes MTI an attractive tool to study the earliest brain changes in the 
continuum of cognitive decline at old age. In a former study using volumetric 
MTI, we demonstrated widespread brain changes in patients with MCI in the 
absence of global atrophy.44 In the present study, we were able to locate these 
abnormalities, as we observed structural damage in both GM and WM. 
One of the major strengths of this study is the robust segmentation method that 
was used. The segmentation procedure was fully automated, and did not require 
human interference. In addition, we were able to include fairly large groups 
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of patients and controls. Patients were recruited from a general population. 
Potential limitations include the clinical diagnoses that were used for AD and 
MCI. Especially with respect to MCI, there is a lack of agreement between 
criteria. We used the criteria for amnestic MCI as proposed by Petersen et al.48;49 
This may have resulted in an underestimation of the number of MCI patients, as 
memory is not the first failing cognitive domain in all elderly people. However, 
the application of the Petersen criteria resulted in the inclusion of a MCI patient 
group highly suitable for investigating the earliest changes in AD. 
In conclusion, using MTI we found evidence for structural brain changes related 
to cognitive impairment that is present in both GM and WM of patients with 
MCI and AD. This implies that cerebral changes can be detected in GM and WM 
even before patients are clinically demented. Our results suggest that vascular 
pathology and Alzheimer-type pathology coexist in the brain even in the earliest 
stages of AD. These findings raise the question of how the MTI changes found in 
this study are distributed over the GM and WM. Further study is currently being 
performed to address this issue.
3
Lobar Distribution of Changes in Gray Matter and White 
Matter in Memory Clinic Patients: Detected Using 
Magnetization Transfer Imaging
American Journal of Neuroradiology. 2007;28:1938-42
A.C.G.M. van Es
W.M. van der Flier
F. Admiraal-Behloul
H. Olofsen
E.L.E.M. Bollen
H.A.M. Middelkoop
A.W.E. Weverling - Rijnsburger
J. van der Grond
R.G.J. Westendorp
M.A. van Buchem
Chapter 3
28
Abstract
Objective 
Previous studies have shown involvement of both gray matter (GM) and white 
matter (WM) in mild cognitive impairment (MCI) and Alzheimer disease (AD). 
In this study, we assessed the lobar distribution of the GM and WM pathology 
over the brain and the association of lobar distribution with global cognitive 
decline.
Methods 
Fifty-five patients with AD, 19 patients with MCI, and 43 subjects with normal 
cognitive function participated in this study. GM and WM were segmented 
on dual fast spin-echo and fluid-attenuated inversion recovery MR images. 
A custom template representing anatomic areas was applied. Magnetization 
transfer imaging (MTI) peak height and mean magnetization transfer ratio 
(MTR) provided measures for structural brain damage.
Results 
Both mean MTR and MTI peak height showed that patients with AD had 
more structural brain damage in the GM of all lobes compared with controls. 
Patients with MCI had lower GM peak height compared with controls for the 
temporal and frontal lobe. WM peak height was lower for all lobes investigated 
for patients with both AD and MCI. WM mean MTR was lower in the frontal, 
parietal, and temporal lobes for patients with AD compared with controls. Age 
and both temporal GM peak height and mean MTR were the only parameters 
that predicted cognition.
Conclusion 
This study shows that in addition to more focal GM MTI changes in the temporal 
and frontal lobes, widespread WM changes are present in the earliest stages of 
AD. This might point to an important role for WM pathology in the earliest stage 
of AD.
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Introduction
Alzheimer disease (AD) is a neurodegenerative disorder that is characterized 
neuropathologically by extracellular deposits of amyloid β and intracellular 
neurofibrillary tangles in the gray matter (GM).32 In addition to this GM 
pathology, evidence is accumulating that vascular pathology also plays an 
important role in the development of AD.9;22;31 This vascular pathology is 
presumed to be reflected in white matter (WM) abnormalities on MR imaging. 
These WM changes can be seen as WM hyperintensities (WMH) on conventional 
MR imaging (eg, fluid-attenuated inversion recovery [FLAIR] or T2-weighted 
MR imaging) but might also affect WM outside these visible lesions.61;62 
Magnetization transfer imaging (MTI) is a quantitative MR imaging technique, 
which is highly sensitive to structural brain changes.40;41 Although MTI has been 
developed to study WM changes, it is also sensitive to changes in tissue structure 
of the GM.43;58-60 This makes MTI an attractive tool to study the earliest brain 
changes in both WM and GM in the continuum of cognitive decline in old age. 
Previous MTI studies investigating the distribution of brain changes over the 
lobes in AD and mild cognitive impairment (MCI) found changes located in the 
temporal lobe42;63 but changes outside this lobe were also detected.44 However, 
in these studies, GM and WM were taken together, so no differentiation could 
be made as to whether the observed changes were attributable to GM or WM. 
It is conceivable that there are differences in the distribution of GM and WM 
damage over the lobes. GM damage is thought to originate from the temporal 
lobe. However, WM damage can be expected to have a more diffuse distribution 
because it is known that WMH are diffusely distributed over the brain.64 
Therefore, the aim of the present study was to investigate how brain changes, as 
detected by MTI, are distributed over the GM and WM in both MCI and AD. 
In addition, we investigated the association between structural brain changes, as 
detected by MTI, and global cognitive decline.
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Methods
Patients
Elderly patients who were consecutively referred to our outpatient memory 
clinic participated in this study. Fifty-five patients with probable AD, 19 patients 
with MCI, and 43 subjects with normal cognitive function were included. 
The healthy group included 19 patients who were evaluated for memory 
complaints but who had no detectable cognitive deficits on neuropsychological 
testing and 24 volunteers without memory complaints who were recruited 
through an advertisement in a local newspaper. All subjects were evaluated for 
memory complaints by using a standardized dementia screening that included 
a detailed medical history, a general internal and neurologic examination, 
laboratory tests, neuropsychological testing including the Mini-Mental State 
Examination (MMSE)47, and MR imaging of the brain. Diagnoses were made 
in a multidisciplinary consensus meeting according to the National Institute 
of Neurologic and Communicative Disorders and Stroke-Alzheimer Disease 
and Related Disorders Association criteria for probable AD6 and the criteria 
according to Petersen et al for MCI.48;49 Patients and controls were included if 
they met the following criteria: 1) older than 60 years, 2) no other neurologic or 
psychiatric illness, and 3) no abnormalities on MR imaging other than WMH or 
an incidental small lacunar lesion (≤5 mm in diameter). This study was approved 
by the local medical ethics committee. Written informed consent was obtained 
from all subjects or from a close relative if a patient was demented. 
MR Imaging Data
MR imaging was performed on a 1.5T MR imaging system (Philips Medical 
Systems, Best, the Netherlands). Conventional dual fast spin echo (48 axial 
slices; slice thickness = 3 mm; no gap; TR/TE = 3,000/27, TI = 120 ms; flip angle 
= 90°; FOV = 220 mm; matrix 256 x 256) and FLAIR (48 axial sections, section 
thickness = 3 mm, no gap, TR/TE = 8,000/100, TI = 2,000 ms; flip angle = 90°, 
FOV = 220 mm, matrix = 256 x 256) sequences were obtained in all patients. The 
line through the inferior border of the genu and splenium of the corpus callosum 
defined the direction of scanning. MTI of the brain was performed by using a 
3D gradient-echo pulse sequence (28 axial sections, section thickness = 5 mm, 
no gap, TR/TE = 106/6 ms, flip angle = 12°, FOV = 220 mm, matrix = 256 
x 256) (a sinc-gauss-shaped saturation pulse 1,100 Hz below the frequency of 
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water was added).50 These scanning parameters were chosen to minimize T1 and 
T2 weighting, resulting in a proton-attenuation (PD) contrast in the absence of 
magnetization transfer (MT) saturation pulses. Two consecutive sets of images 
were acquired; the first was performed in combination with the MT saturation 
pulse, and the second, without. 
Image Postprocessing
Images were analyzed by using Software for Neuro-Image Processing in 
Experimental Research, an in-house- developed program for image processing.65 
Briefly, the postprocessing included the following steps (Fig 3.1): First, the PD 
image was used to create an intracranial mask. The PD, T2, and FLAIR images 
were combined to generate segmentations of GM, WM, WMH, and CSF. 
Subsequently, a custom template was applied to exclude the cerebellum, brain 
stem, and basal ganglia from analysis and to determine the anatomic regions of 
the frontal, temporal, parietal, and occipital lobes (Fig 3.2).66 The boundaries 
between lobes in this custom-designed template were drawn according to Zilles 
and Rehkämper.67 All structures rostral of the mesencephalon and cerebellum 
were considered supratentorial. All interfaces between CSF, GM, and WM 
were eroded 1 voxel to minimize partial voluming effects. Finally, these masks 
were coregistered to the MT images. The magnetization transfer ratio (MTR) 
for each voxel within the mask was calculated automatically by using the 
formula MTR = ((M0 − Ms) / M0) x 100%, in which Ms represents the signal 
intensity of voxels with saturation and M0 represents the intensity of voxels 
without saturation. In the resulting MTR map, voxel values represented the 
percentage of signal-intensity loss caused by transfer of magnetization of the 
saturated immobile macromolecular-bound to the free water pool of protons.50 
Mean MTR was defined as the average MTR of all voxels in the GM or WM 
of a given a lobe. The frequency distributions of MTR values were displayed as 
MTR histograms of the GM and WM of each lobe, respectively.68 From each 
histogram, the peak height was derived. The peak height of the histogram was 
determined as a measure of the frequency of appearance of the most common 
MTR value and reflected the amount of remaining normal brain tissue. This peak 
height was normalized for lobar size by dividing the number of voxels on the 
peak by the total number of segmented voxels. The normalized peak height thus 
obtained was a measure reflecting the amount of remaining normal brain tissue 
in a specific lobe, independent of lobar size and atrophy.46 
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Figure 3.1. A, Automatic segmentation process. First, the PD image is used to create an 
intracranial segmentation. B, The PD, T2, and FLAIR images are combined to generate 
segmentations of GM and WM. C, After that, the masks are coregistered to the MTI 
image. D, Finally, the custom template representing the frontal, parietal, temporal, and 
occipital lobes, drawn according to Zilles and Rehkämper, was applied (also see Fig 3.2).
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Statistical Analysis
Statistical Package for the Social Sciences for Windows (Release 10.0; SPSS, 
Chicago, Ill) was used for data analysis. Categoric variables were analyzed by using 
a Chi-square test. Differences in group means were analyzed by using analysis 
of variance with post hoc Bonferroni tests. Independent associations between 
structural brain abnormalities and MMSE across all groups were assessed by 
simultaneously entering the GM and WM peak heights for all regions, atrophy, 
WMH volume, age, and sex in a linear regression model. The level of statistical 
significance was set at p = 0.05.
Figure 3.2. 3D example of the anatomic template used in this study. The boundaries 
between the lobes in this template were drawn according to Zilles and Rehkämper.
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Table 3.1 Demographic and clinical characteristics.
Normal Cognition 
(n=43)
MCI
(n=19)
AD
(n=55)
Sex (m/f)a 15/28 5/14 28/27
Age (yr) 73 (± 7) 77 (± 6) 74 (± 8)
Education (yr) 11 (± 4) 10 (± 4) 10 (± 4)
MMSE 28 (± 2) 26 (± 1)  18 (± 5)b
WMH vol. (mL) 6.4 (± 8) 4.7 (± 8) 6.5 (± 9)
Atrophyc 74.7 (± 4) 72.5 (± 5) 71.2 (± 5)d
Data are represented as mean (± SD). 
a Chi-Square test 
b Differs from group with normal cognition and MCI (p < 0.001). 
c Atrophy is defined as total parenchyma volume divided by intracranial volume. 
Therefore, the numbers represents the % of intracranial volume occupied by brain 
parenchyma. 
d Differs from group with normal cognition (p < 0.01).
Table 3.2 Gray and white matter peak height of the frontal, parietal, temporal and 
occipital lobe. 
Normal Cognition 
(n=43)
MCI
(n=19)
AD
(n=55)
Frontal Gray Matter 69.8 (± 13.0) 57.4 (± 14.7)a 53.2 (± 11.0)a
White Matter 161.6 (± 20.0) 140.3 (± 28.1)a 135.7 (± 24.3)a
Parietal Gray Matter 69.5 (± 14.4) 59.5 (± 15.5) 55.4 (± 10.7)a
White Matter 167.5 (± 23.2) 145.6 (± 26.8)a 146.2 (± 24.9)a
Temporal Gray Matter 82.3 (± 12.8) 68.8 (± 11.4)a 62.2 (± 9.2)a
White Matter 144.4 (± 19.3) 126.8 (± 25.0)a 126.9 ( ± 18.0)a
Occipital Gray Matter 80.0 (± 16.4) 75.7 (± 10.0) 68.3 (± 9.5)a
White Matter 143.9 (± 22.7) 125.0 (± 24.1)a 126.9 (± 18.0)a
Data are represented as mean (± SD). The peak height of the histogram was determined 
as a measure of the frequency of appearance in the most common MTR value and 
reflects the amount of remaining normal brain tissue (x 103). 
a = Differs from group with normal cognition (p < 0.01).
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Results
There were no differences in sex, age, education, and WMH volume between 
groups (Table 3.1). As expected, patients with AD had lower MMSE scores than 
patients with MCI and subjects with normal cognition. Furthermore, patients 
with AD had more atrophy compared with subjects with normal cognition. 
The GM and WM peak heights of the frontal, parietal, temporal, and occipital 
lobes for each diagnostic group are displayed in Table 3.2. Patients with AD 
had a lower GM and WM peak height for all lobes compared with subjects with 
normal cognition. Patients with MCI had a lower GM peak height compared 
with controls for the temporal and frontal lobe. WM peak height was reduced for 
all lobes investigated when comparing patients with MCI and AD with subjects 
with normal cognition. There were no differences between patients with MCI 
and AD. Mean MTRs of the frontal, parietal, temporal, and occipital GM and 
WM are shown in Table 3.3. The mean MTR of all regions, except the occipital 
Table 3.3 Gray and white matter mean MTR of the frontal, parietal, temporal and 
occipital lobe.
Normal Cognition 
(n=43)
MCI
(n=19)
AD
(n=55)
Frontal Gray Matter 27.1 (±1.9) 26.0 (± 2.0) 25.5 (± 1.9)a
White Matter 35.0 (± 1.0) 34.5 (± 1.3) 34.4 (± 1.1)a
Parietal Gray Matter 26.9 (± 2.0) 26.2 (± 1.7) 25.7 (± 1.9)a
White Matter 34.8 (± 1.0) 34.6 (± 1.3) 34.3 (± 1.3)a
Temporal Gray Matter 29.7 (± 1.4) 28.9 (± 1.3) 27.6 (± 1.5)a
White Matter 34.7 (± 1.1) 34.5 (± 1.2) 34.2 ( ± 0.9)a
Occipital Gray Matter 28.8 (± 1.9) 29.1 (± 1.5) 27.9 (± 1.9)a
White Matter 33.8 (± 0.9) 33.8 (± 1.1) 33.4 (± 1.1)
Data are represented as mean (± SD).
a = Differs from group with normal cognition (p < 0.01).
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Figure 3.3. Scatterplot of MMSE versus temporal gray matter peak height (Pearson’s r = 
0.67). : Cognitive normal,    : MCI , : AD. In a linear regression analysis with the GM 
and WM peak heights of all lobes, WMH volume, atrophy, age and sex as predictors, 
temporal GM peak height was, along with age, the only parameter to independently 
predict MMSE (p < 0.001; Beta (SE) = 0.75 (0.03)). This implies that if the MMSE 
decreases 1 point the peak height will decrease with 0.75. MMSE = points scored on 
Mini Mental State Examination. Temporal GM Normalized Peak height = number of 
voxels on the peak of the temporal GM MT histogram / total number of temporal GM 
voxels x 103.
WM, differed between patients with AD and subjects with normal cognition. No 
differences were found between patients with MCI and AD or between patients 
with MCI and subjects with normal cognition. 
When the peak heights for all regions, atrophy, WMH volume, age, and sex 
were entered simultaneously in a linear regression model, age (β [SE] = 0.41 
[0.02]); p = 0.001) and temporal GM peak height (β [SE] = 0.75 [0.03]) p = 
.001) (Fig 3.3) were the only parameters that predicted cognition. Similar results 
were found for mean MTR because age (β [SE] = 0.19 [0.02]; p = 0.001) and 
temporal GM mean MTR (p = 0.001; β [SE] = 0.74 [0.03]) predicted cognition 
in this model. This analysis was performed across all 3 groups. Within the groups, 
none of the parameters were associated with MMSE (p = 0.05).
M
M
S
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Temporal GM Normalized Peak Heigth
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Discussion
In this study, we found that patients with AD showed widespread MTI changes 
in both GM and WM. Widespread structural changes were also found in the WM 
of patients with MCI in addition to GM changes in the temporal and frontal lobes. 
When all peak heights or mean MTRs of all lobes were assessed simultaneously, 
GM changes of the temporal lobe were found to be independently associated 
with MMSE. Furthermore, our study is in line with previous studies that 
reported that MTI peak height is the most sensitive MTR parameter in detecting 
brain pathology.42;46;69 Mean MTR only detected differences between patients 
with AD and subjects with normal cognition, whereas peak height also detected 
differences between subjects with normal cognition and patients with MCI. 
These findings are in line with previous quantitative MR imaging studies 
detecting WM and GM damage in MCI and AD.54;61 However, in all the previous 
studies investigating the lobar distribution of  MTR changes in patients with MCI 
and AD, GM and WM were taken together.42;44;63 Therefore, it remained unclear 
whether the widespread MTR changes found in AD and MCI were attributable 
to damage in the GM only. This study combined a GM/WM segmentation with 
the lobar localization of the MTR changes in the cerebrum of patients with MCI 
and AD. 
GM damage found in the group of patients with AD involved all lobes investigated. 
This is in line with neuropathologic findings showing that the entire cerebrum 
is involved in the more-advanced stages of the disease.32 In our study, MTR 
changes were detected in the temporal and frontal lobes of patients with MCI. 
The temporal GM is the region where the earliest neuropathologic changes are 
found in AD. Neuropathologic changes of this region reflect disease progression 
because the atrophy rate of this region is known to be a marker of disease 
progression.70 This also explains the strong and specific association between 
temporal GM peak height and MMSE. Furthermore, GM pathology affects the 
frontal lobe in MCI.71 Our MTI findings seem to confirm this involvement of 
both temporal and frontal GM in MCI. 
In the WM of patients with AD, damage has been demonstrated in various 
regions of interest, including the frontal, temporal, parietal, and occipital lobes, 
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by using diffusion weighted imaging.61;62 In addition, diffusion tensor imaging 
showed WM damage not only inside but also outside the temporal lobe in 
patients with MCI.54 In this MTI study, we were able to expand on these former 
studies because we showed widespread WM damage in all lobes of patients 
with both MCI and AD, applying volumetric analysis. We hypothesize that the 
observed WM changes are caused by chronic hypoperfusion based on cerebral 
small vessel disease. Age-related WMH are a well-documented manifestation 
of such small-vessel disease.35 However, it is unlikely that the observed MTI 
changes in lobar WM can only be attributed to the relatively small volumes of 
WMH that we found in our patients. Because it has been demonstrated that MTI 
is more sensitive to the presence of structural brain changes than conventional 
MR imaging sequences40;41, changes in the normal-appearing WM (NAWM) 
probably also contribute to the observed MTI changes in the WM. This was 
confirmed by our study because a separate assessment of the NAWM did not 
yield peak heights that were significantly different from the whole WM peak 
heights. We presume that these changes are more subtle manifestations of the 
same pathology underlying WMH. These findings are in keeping with recent 
neuropathologic studies showing that microvascular disease is not only almost 
universally present in MCI but might also play an important role in cognitive 
decline.22;72;73 
One of the major strengths of this study is the robust segmentation method 
that was used. The segmentation procedure was fully automatic and did not 
require human interference. Erosion guaranteed that partial voluming effects 
did not affect our results. Therefore, we are confident that the results are not 
caused by volume loss. Furthermore, volumetric analysis allowed us to include 
all cortical GM and WM voxels except those that were left out after erosion. In 
addition, we were able to include fairly large groups of patients and controls. 
A potential limitation of this study was that our in-house-developed template 
of the anatomic regions of the cerebral lobes is somewhat artificial because it 
is impossible to define exact boundaries for the WM between lobes. However, 
the segmentation results appeared appropriate. Our study shows that MTI is a 
sensitive tool for detecting WM and GM damage in the early stages of AD, when 
peak height is used as an outcome measure. Therefore, MTI might have potential 
value as a diagnostic tool or as a surrogate marker of disease in both MCI and 
AD. However, the predictive value of MTI needs further investigation, especially 
by studies with a longitudinal design. 
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Conclusion
The conclusion drawn from this study is that brain damage, as detected by MTI, 
is widespread over the lobes in patients with both AD and MCI. GM damage 
is more focally present in the temporal and frontal lobes of patients with MCI. 
This is in line with the neuropathologic knowledge that GM damage originates 
from the temporal lobe in AD and explains the independent association between 
temporal GM peak height and cognitive decline. WM damage was found in all 
4 lobes of the patients with MCI investigated in this study. This might point to 
the involvement of a diffuse process affecting the WM even before patients are 
clinically demented and could be explained by the presence of diffuse vascular 
pathology.
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Abstract 
Objective
Although total cerebral blood flow (tCBF) is known to be related to age, less 
is known regarding the associations between tCBF and the morphologic 
changes of the brain accompanying cerebral aging. The purpose of this study 
was to investigate whether total cerebral blood flow (tCBF) is related to white 
matter hyperintensity (WMH) volume and/or cerebral atrophy. Furthermore, 
we investigate whether tCBF should be expressed in mL/min, as was done in 
all previous MR studies, or in mL/100 mL/min, which yielded good results in 
precious SPECT, PET and perfusion MRI studies investigating regional cerebral 
blood flow.
Methods
Patients were included from the nested MRI sub-study of the PROSPER study. 
Dual fast spin echo and FLAIR images were obtained in all patients. In addition, 
single slice phase contrast MR angiography was used for flow measurements in 
the internal carotids and vertebral arteries. TCBF was expressed in both mL/
min and mL/100 mL/min. 
Results
We found a significant correlation between tCBF in mL/min and both age (r = 
-0.124; p ≤ 0.001) and parenchymal volume (r = 0.430; p ≤ 0.001). We found 
no association between tCBF in mL/min and %-atrophy (r = -0.077; p = 0.103) 
or total WMH volume (r = -0.069; p = 0.148). When tCBF as expressed in 
mL/100 mL/min the correlation between tCBF and age was no longer found (r 
= -0.001; p = 0.985). Multivariate regression analyses corrected for age showed a 
significant correlation between tCBF in mL/100 mL/min and WMH volume (r 
= -0.106; p = 0.044). No significant association between tCBF in mL/100 mL/
min and %-atrophy was found. 
Conclusion
From this study we conclude that, when evaluating tCBF alterations due to 
various pathologies, tCBF should in mL/100 mL/min instead of mL/min. 
Furthermore, changes or differences in WMH volume should be accounted for.
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Introduction
Determination of total cerebral (tCBF) blood flow to the brain, by measuring 
flow in the internal carotid arteries (ICA) and posterior circulation has 
been applied in patients with obstructive disease of the ICA or posterior 
circulation74;75, arteriovenous malformations76, acute neurotrauma77, cerebral 
ischemia78, and the evaluation of vascular interventions such as bypass surgery79 
or carotid endarterectomy.80 In these studies tCBF was expressed in mL/min, 
regardless of the volume of the supplied brain. However, for interpretation of 
the data, Buijs et al. have published a flow decrease of 4.8 ml/min per year in 
a normal population.81 In addition, Hendrikse and coworkers have shown that 
the distribution of flow in the brain is strongly influenced by the anatomy of 
the circle of Willis.82 Determination of flow to the vessels that supply the brain 
seems especially useful in subjects in whom it may be expected that the volume 
flow is getting too low to maintain normal cerebral blood flow and function such 
as elderly subjects or patients suffering from Alzheimer’s disease, diabetes or 
atherosclerosis. 
White matter hyperintensities (WMHs) and cerebral atrophy are common 
findings in the aging population and their prevalence increases with age.83-85 On 
T2-weighted Magnetic Resonance Imaging (MRI) WMHs are seen as patchy 
or diffuse areas of hyperintensity. Clinically they have been associated with 
gait disturbance86, cognitive impairment87;88, mood disorder89 and dementia90. 
Changes in CBF might also reflect cerebral changes such as atrophy. In addition 
to an increased WMH load, cerebral atrophy is a common finding in the elderly 
and a manifestation of neuronal degeneration contributing to cognitive decline 
and dementia.91;92 
Low regional cerebral blood flow is one of the processes thought to underlie the 
development of both WMHs and atrophy as strong associations with vascular 
risk factors exist.83;93-97 Moreover, declining blood pressure has also been 
associated with global brain atrophy.98 The associations between flow and WMHs 
have been investigated in positron emission topography (PET), single photon 
emission topography (SPECT) and perfusion weighted MRI studies, showing 
a relationship between low regional cerebral blood flow (rCBF) and WMHs in 
small populations.99-106 All these studies expressed the rCBF in mL/100mL/
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min. Therefore, contrary to previous MR studies, these flow measurements are 
not influenced by potential influence of the volume of the provided (part of the) 
brain. 
Despite this evidence for an important role of the cerebral blood supply in the 
development of both WMHs and atrophy, only one study has investigated the 
association between tCBF and WMHs.107 This study found that patients in 
the quartile with the highest tCBF had a lower number and severity of WMHs 
suggesting an association between tCBF and the presence of WMHs. However 
this study has two major limitations. First, WMHs were scored quantitatively 
and analyzed in quartiles. Second, similar to previous MR studies, the tCBF was 
expressed as mL/min and therefore the effect of parenchyma volume was not 
taken into account. The aim of this study is two-fold: 1) to investigate whether 
tCBF is related to WMHs volume and/or cerebral atrophy and 2) whether these 
associations are influenced by expressing tCBF in mL/100 mL/min instead of 
mL/min.
Methods
Ethics Statement
The PROSPER study had ethics review board approval of all locations and 
written informed consent of all participants. In addition, the Leiden University 
Medical Center institutional ethics review board approved the protocol for the 
prospective MR study and subsequent retrospective analyses. Moreover, all 
participants gave written informed consent. Participants of this MR study also 
agreed with future retrospective analysis of their MR data for research purposes. 
Patients
Patients were included from the nested MRI substudy of the PROspective Study 
of Pravastatin in the Elderly at Risk (PROSPER). Inclusion criteria for this study 
were: men or women aged 70–82 years; total cholesterol 4.0–9.0 mmol/L; stroke, 
transient ischemic attack, myocardial infarction, arterial surgery, or amputation 
for vascular disease > 6 months before study entry; ≥ of the following risk factors 
for vascular disease: current smoker; hypertension, currently receiving drug 
treatment; known diabetes mellitus or fastening blood glucose >7 mmol/L. 
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Exclusion criteria have been described in detail elsewhere.108 All subjects had 
a history of, or were at increased risk for, vascular disease. In total, 464 subjects 
underwent MRI including flow measurements. Seventeen patients dropped out 
because flow measurements of the ICAs or vertebral arteries or segmentation 
of the intracranial structures failed because of technical problems. Patient 
characteristics are shown in Table 4.1. 
Table 4.1. Demographic and clinical characteristics.
Continuous variates means (SD)
Age, y 75 (3)
Systolic blood pressure, mm Hg 158 (23)
Diastolic blood pressure, mm Hg 86 (11)
Total cholesterol, mmol/L 5.8 (0.8)
LDL cholesterol mmol/L 3.9 (0.7)
HDL cholesterol, mmol/L 1.2 (0.3)
Triglycerides, mmol/L 1.5 (0.7)
Total WMH volume, ml 5.2 (9.6)
Categorical variates n (%)
Male gender 262 (56)
Current smoker 96 (21)
History of diabetes 76 (16)
History of hypertension 293 (63)
History of myocard infarction 56 (12)
History of stroke or TIA 75 (16)
History of any vascular disease 202 (44)
MRI stroke 178 (38)
LDL = Low-density lipoprotein
HDL = High-density lipoprotein 
WMH = White matter hyperintensity
n = number of patients
% = percentage of patients
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Figure 4.1. Single slice phase contrast MR angiography. Saggital MRA scout image 
of the main brain feeding arteries (A). The white slab represents the position of the 
transverse angiographic phase image. This image shows the carotid arteries (arrows) 
and vertebral arteries (arrowheads) over which flow was measured (B).
Figure 4.2. The segmentation process using SNIPER (Software for Neuro-Image 
Processing in Experimental Research). T2-weighted image (A) and FLAIR image (B). 
Result of automated segmentation process based on both sequences (C).
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MRI
All imaging was erformed on an MR system operating at a field strength of 1.5 
Tesla (Philips Medical Systems, Best, The Netherlands). Dual fast spin echo (TE 
= 27/120 msec; TR = 3000 msec; flip angle = 90°; section thickness = 3 mm; 
number of sections = 48; no section gap; whole brain coverage; FOV = 220; scan 
matrix = 2566204; nsa = 1) and fluid-attenuated inversion recovery (FLAIR) 
(TE = 100 msec; TR = 8000 msec; flip angle = 90°; section thickness = 3 mm; 
sections = 48; no section gap; whole brain coverage; FOV = 220; scan matrix = 
256 x 204, nsa = 1) images were obtained from all subjects. In addition, single 
slice phase contrast MR angiography (TR/TE = 16/9 msec; flip angle = 7.5°; 
slice thickness = 5 mm; FOV = 250; RFOV = 75%; scan percentage = 80%; matrix 
= 56; 8 signal averages) with a velocity encoding of 100 cm/second was used 
for flow measurements.109 The scans were performed in a plane perpendicular to 
the left and right internal carotid artery and the vertebral arteries, at the level of 
the vertical segment of the petrous portion of the internal carotid artery (Figure 
4.1). 
Image analysis
WMHs, intracranial volume, and brain parenchyma were assessed 
semiautomatically. That is, segmentations of WMHs, intracranial volume, and 
brain parenchyma were generated automatically using Software for Neuro-
Image Processing in Experimental Research SNIPER), an in-house-developed 
program for image processing (Figure 4.2.). The WMH volume was calculated 
automatically.39 Infarcted areas were counted being CSF. All measurements 
were performed blinded to subject identity, age and sex. Atrophy was calculated 
using the formula: atrophy (%) = ((intracranial volume–parenchymal volume)/
intracranial volume) x 100%. For tCBF assessment, images were analyzed using 
the software package FLOW®.110 For this analysis a region of interest (ROI) was 
manually drawn around the left and right internal carotid and the right and left 
vertebral arteries in the magnitude image by one observer (ACGMvE). The flow 
in these four vessels was summed giving the tCBF in mL/min. TCBF was also 
expressed in mL blood per 100 mL of brain parenchyma per min (mL/100 mL/
min).
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Figure 4.3. Association 
of tCBF with age and 
parenchyma volume. 
Scatterplot of tCBF 
(mL/sec) versus age (yrs) 
(r = –0.124; p = 0.008) 
(A) and parenchymal 
volume (mL) (r = 0.430; 
p≤.001) (B). Box-and-
whisker plot of average 
tCBF (mL/100 mL/min) 
found for each age (yrs) 
(C).
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Statistical analysis
SPSS for Windows (release 12.0; SPSS, Chicago, IL) was used for data analysis. 
Linear regression analysis was used to investigate correlations between 
parameters. Age was entered as an independent variable as previous studies 
have reported an inverse correlation between tCBF and age.81;82 The level of 
significance was set at p < 0.05. 
Results
The MRI characteristics of the subjects included in this study are shown in Table 
4.2. In this study an inverse correlation between age and tCBF in mL/min was 
found (r = –0.124; p = 0.008; Figure 4.3a). This corresponds with an annual flow 
decrease of 6.2 mL. Figure 4.3b shows the association between tCBF in mL/
min and parenchymal volume, indicating a significant correlation (r = 0.430; p 
≤ 0.001) between the two. When tCBF was expressed in mL/100 mL/min the 
correlation between tCBF and age was no longer found (r = –0.001; p = 0.985) 
(Figure 4.3c). The volume flow (mL/min) in the individual vessels contributing to 
the tCBF did not show an association with age. However, significant correlations 
with parenchymal volume were found for both left (r = 0.114; p = 0.016) and 
right (r = 0.119; p = 0.012) vertebral artery and both left (r = -0.293; p ≤ 0.001) 
and right (r = 0.284; p ≤ 0.001) internal carotid artery. We found no association 
between tCBF in mL/min and %-atrophy (r = –0.077; p = 0.103) or total WMH 
Table 4.2. MR characteristics.
mean SD minimum maximum
tCBF in mL/min 510 87.4 315 846
tCBF in mL/100mL/min 50.4 7.8 30.9 74.3
Parenchymal vol. (mL) 1016 98.7 752 1259
Atrophy (%) 27.3 3.2 15.6 38.4
tot. WMH vol. (mL) 7.1 10.6 0 76.2
tCBF = Total cerebral blood flow
WMH = White matter hyperintensity
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Figure 4.4. Association of tCBF (in mL/min) with atrophy and WMH volume. 
Scatterplot of tCBF (mL/sec) versus atrophy (%) (r = -0.077; p = 0.103) (A) and total 
WMH volume (mL) (r = -0.069; p = 0.148) (B). Atrophy was defined by the following 
equation: intracranial volume - parenchyma volume/intracranial volume. Therefore, 
number reflects the percentage of intracranial volume occupied by cerebrospinal fluid.
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volume (r = –0.069; p = 0.148) (Figure 4.4a & 4.4b). TCBF in mL/100 mL/
min was associated with WMH volume (r = –0.106; p = 0.044) (Figure 4.5). No 
significant association between tCBF in mL/100 mL/min and%-atrophy was 
found. Furthermore, no association between parenchyma volume and WMH 
volume existed (r = 0.05; p = 0.317).
Discussion
The findings of the present study are fourfold. First, the most important finding is 
the strong correlation between tCBF in mL/min and both age and parenchymal 
volume. However, the association between tCBF and age was no longer 
found when flow was expressed in mL/100 mL/min. Second, when analysed 
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Figure 4.5. Association of tCBF (mL/100 mL/min) with WMH volume. Scatterplot 
of tCBF (mL/100 mL/min) versus WMH volume (mL).
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separately, the flow in mL/min over each individual vessels contributing to the 
cerebral blood flow was associated with parenchymal volume as well. Third, 
when expressing tCBF in mL/100 mL/min a correlation between tCBF and 
total WMH volume was found. Fourth, no association was found between tCBF 
in mL/100 mL/min and atrophy. 
In the present study we found a significant association between tCBF in mL/min 
and age, corresponding with an annual flow decrease of 6.2 mL. This confirms 
a previous study by Buijs et al. showing an average flow decrease of 4.8 mL/
min per year.81 The slightly higher decline of tCBF in mL/min with age found 
in our study is likely due to the fact that we included relatively older subjects 
and that all subjects had cardiovascular disease or risk factors for developing 
this condition. A strong association between tCBF in mL/min and parenchymal 
volume was found and remained after the adjustment for age. However, when 
the tCBF was expressed in mL/100 mL/min no significant association with age 
was found. Therefore it seems that parenchymal volume underlies the previous 
reported associations between age and tCBF mL/min. 
In the present study the tCBF is obtained by the summation of the volume flow 
over the two carotid arteries and the two vertebral arteries. If the blood flow over 
these individual vessels is analysed separately, no association between the flow 
volume and age is found. This may be due to variation caused by the different 
conformations of the Circle of Willis as described by Hendrikse et al.82 However, 
an association with parenchymal volume, the most important determinant of 
cerebral blood flow, was still present. Our data show a much higher association 
between the volume flow over internal carotid arteries and parenchymal volume 
than for the flow over the vertebral arteries. Both vertebral arteries contribute to 
the posterior circulation, which for a large part supplies the cerebellum. In this 
respect, it could be that parenchymal volume loss due to aging is different in the 
cerebellum than in the cerebrum. 
Atherosclerotic patients have a relative high prevalence of WMHs and atrophy. In 
our population suffering from vascular pathology and cardiovascular riskfactors 
it was shown that tCBF in mL/100 mL/min was associated with WMH volume. 
No association was found between tCBF in mL/100 mL/min and atrophy. 
Although we can not draw a solid conclusion from our cross-sectional study, this 
finding indirectly suggests that blood flow to the brain probably plays a minor 
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role in the development of atrophy. However, atrophy is best assessed using two 
time points, therefore the absence of associations between atrophy and tCBF 
should be replicated in a longitudinal study. 
A potential limitation of our study is the small age range of the included patients. 
All patients in the present study were aged between 72 and 85 years, which 
makes extrapolation of our results to younger individuals arbitrary. On the other 
hand, WMHs and atrophy are highly prevalent and are thought to be clinically 
significant in this specific age span. Furthermore, the crosssectional design of 
this study could not elucidate whether decreased tCBF precedes WMH or that 
reduced brain function due to the presence WMH reduces tCBF flow parameters.
Conclusion
In conclusion, we found that tCBF in mL/min is strongly associated with the 
parenchymal volume rather than age. Although this finding seems obvious, 
this is the first study showing this strong association. In addition, we found a 
much weaker association between tCBF in mL/100 mL/min and the severity 
of WMHs. These findings have important implications for future studies in 
which flow measurements are being used as diagnostic tool: All future volume 
flow measurements should be expressed in mL/100 mL/min rather than mL/
min. Moreover, when studying elderly patients or patients with a pathological 
increase of WMHs, such as diabetic type II subjects, tCBF measurements should 
also be corrected for WMH volumes.
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Abstract
Objective
Vascular pathology is increasingly seen as a factor contributing to the development 
of Alzheimer’s disease (AD). With this in mind we hypothesized that this vascular 
pathology could be directly detected in the arteries contributing to the cerebral 
circulation of mild cognitive impairment (MCI) and AD patients by means of 
wall shear stress (WSS) measurements. 
Methods
In this study we investigated the mean wall shear stress (MWSS), diastolic wall 
shear stress (DWSS) and systolic wall shear stress (SWSS) in the carotid and 
basilar arteries of control subjects (mean age: 72; SD: 8.8), patients suffering 
from MCI (mean age: 76; SD: 6.7), and patients suffering from AD (mean 
age: 72; SD: 8.2) that were consecutively referred to our outpatient memory 
clinic using in-house developed software on gradient echo phasecontrast MRI 
sequences. 
Results
We found that all these parameters were significantly lower in the carotid arteries 
of patients suffering from AD or MCI when compared to control subjects. In the 
basilar artery only DWSS was lower in MCI or AD patients compared to control 
subjects. In none of the arteries a difference was found for any WSS parameter 
between MCI and AD patients. WSS parameters were significantly associated 
(corrected for age and sex) with the degree of cognitive impairment. 
Conclusion
Increased vascular pathology, as expressed by lower WSS measures, was found in 
patients suffering from MCI and AD compared to normal controls. This might 
point to the involvement of vascular pathology in the development of AD.
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Introduction
Evidence is accumulating that the pathophysiology of Alzheimer’s disease (AD) 
extends beyond the presence of neurofibrillary tangles and amyloid plaques. In 
addition to this ‘classical’ AD pathology, a large number of neuropathological 
studies have shown that AD might be more heterogeneous and include a 
cerebrovascular component.9;22;31 In this respect, a large part of AD patients 
exhibit significant cerebrovascular pathology, which constitutes distinct small 
vessel disease of the same degree as found in vascular dementia.111 
Contrary to AD, the role of vascular pathology in mild cognitive impairment 
(MCI) is unknown. MCI is characterized by isolated memory impairment and 
considered a prodrome of AD. Therefore, it could be hypothesized that vascular 
pathology may also be present in this very early stage of the disease. 
Although post-mortem evidence exists for an important role of vascular 
pathology for AD, the physiological status of a vessel is still hard to evaluate 
in vivo. One parameter that reflects the overall status of the vessel is wall shear 
stress (WSS). WSS is the friction force per unit area that is exerted by blood flow 
on the vessel wall and is thought to play a role in the induction and progression 
of atherosclerosis. In general, low WSS is considered as a good indicator for the 
presence of vascular pathology as alterations of wall shear stress might offer a 
unique explanation for the effect produced by different cardiovascular risk 
factors.112 Low WSS has been associated with aging, gender, high systolic blood 
pressure, low highdensity lipoprotein cholesterol, smoking, obesity, intima-
media thickness, the presence of atherosclerotic plaques, history of hypertension, 
history of angina pectoris, history of myocardial infarction and a history of any 
vascular disease.112-123 
In this study, we investigated vascular pathology in normal controls, patients 
suffering from MCI and AD patients by means of measuring the mean WSS, 
diastolic WSS and systolic WSS in the carotid and basilar arteries.
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Methods
Patients
Elderly subjects that were consecutively referred to our outpatient memory 
clinic participated in this study. Forty-six patients with probable AD, 22 patients 
with MCI and 45 subjects with normal cognitive function were included. All 
subjects were evaluated for cognition complaints using a standardized dementia 
screening that included a detailed medical history, a general internal and 
neurological exam, laboratory tests, neuropsychological testing and MRI of 
the brain. In short, neuropsychological testing included a detailed interview, an 
abbreviated version of the Groninger Intelligence Test, the Cambridge Cognitive 
Examination, incorporating the Mini Mental State Examination (MMSE)47, 
the Wechsler Memory Scale and memory subtests from the Alzheimer Disease 
Assessment Scale (word recall and recognition) and Benton Visual Retention 
Test (visual recognition). For the majority of the neuropsychological tests, 
age-based norms were available. Furthermore, tests were interpreted taking 
into account both educational and occupational level. Diagnoses were made 
in a multidisciplinary consensus meeting according to the National Institute of 
Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease 
and Related Disorders association (NINCDS-ADRDA) criteria for probable 
AD.6;48;49 The following criteria were used to diagnose MCI48;49: (1) memory 
complaint, (2) impaired memory function on cognitive testing, (3) preserved 
general cognitive functioning, (4) intact activities of daily living, (5) not 
demented. Patients and controls were included if they (1) were older than 
60 years, (2) had no other neurological or psychiatric illness, and (3) had no 
abnormalities on MRI other than white matter hyperintensities or an incidental 
small lacunar lesion (≤ 5 mm diameter). The diagnosis of MCI was made by 
interpreting the patient’s complete test profile with the education and past 
performance of the patient taken into account. The study was approved by the 
local Medical Ethical Committee. Written informed consent was obtained from 
all subjects or from a close relative if a patient was demented. 
MR Acquisition
MR images of the participants were obtained with a 1.5-tesla clinical MRI scanner 
(Gyroscan ACS-NT 15, Philips Medical Systems, Best, The Netherlands). 
Blood flow was measured in both internal carotid arteries, using a gradient echo 
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phase-contrast MRI sequence. Retrospective cardiac triggering by means of 
a peripheral pulse unit was applied, yielding 16 phases over a cardiac cycle. A 
triggered gradient echo phase-contrast technique (repetition time/echo time 
14.7/9.1 ms; flip angle 7.5°; slice thickness 5 mm; single slice; field of view 250 
mm) was used with 1 NSA (number of signal averages) and retrospective gating 
with the use of the peripheral pulse unit. The scans were performed in a plane 
perpendicular to the internal carotid arteries, 2 cm distal to the bifurcation. 
The images were analyzed using the software package FLOW®[Division of Image 
Processing (LKEB), Department of Radiology, Leiden University Medical 
Center].110;124 With this automatic method, the vessel has to be indicated 
manually, after which the delineation of the vessel is established automatically. 
Flow volume is calculated by integrating the flow velocity values within this 
contour, multiplied with the area. Furthermore, the radius of the vessel is 
calculated based on flow and maximum velocity in the cross section of the vessel. 
Determination of Wall Shear Stress
Velocity profiles in small arteries can be approximated by a 3D paraboloid, this 
model assumes no slip at the vessel wall. The WSS can be calculated by:
WSS = 4μvmax /D  (1)
In which μ represents the blood viscosity (mPa∙s), D the diameter of the lumen 
(m), and vmax the maximum velocity in the cross section of the vessel (m/s). 
Blood is assumed to be a Newtonian fluid and the viscosity is taken as 4.3 mPa∙s. 
The diameter of the vessel can be calculated by using the Hagen-Poiseuille 
formula:
D = √(8Q/vmaxπ)  (2)
In which Q represents the blood flow (ml/min). Equations (1) and (2) combined 
result in: 
WSS = μvmax√(2πvmax/Q)  (3)
With this formula, WSS can be calculated based on parameters reliably assessable 
with velocity-encoded MRI. 110;125
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Table 5.1. Demographic and clinical characteristics.
Controls (n=45) MCI (n=22) AD (n=46)
Age (yrs) 72 (8.8) 76 (6.7) 72 (8.2)
Sex (m/f) 20/25 (44%) 9/13 (41%) 25/21 (54%)
MMSE 28.0 (2.0) 25.8 (1.9) * 18.1 (5.6)**,+
Differs from normal controls:
*  p < 0.05
**  p < 0.01
Differs from MCI:
+ p < 0.005
Table 5.2. Wall shear stress parameters of the carotid and basilar arteries corrected for 
age and sex. 
Controls (n=45) MCI (n=22) AD (n=46)
Carotid arteries
MWSS 1.000 (0.303) 0.794 (0.234)** 0.741 (0.220)***
DWSS 0.754 (0.228) 0.592 (0.185)** 0.563 (0.194)***
SWSS 1.392 (0.491) 1.115 (0.361)* 1.054 (0.339)***
Basilar artery
MWSS 1.474 (0.432) 1.189 (0.293) 1.217 (0.406)
DWSS 1.098 (0.321) 0.839 (0.117)* 0.885 (0.248)*
SWSS 2.002 (0.606) 1.691 (0.490) 1.726 (0.687)
Values are means (SD) in Pascals.
Differs from normal controls:
*  p < 0.05
**  p < 0.01
*** p < 0.001
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Post-Processing
Blood flow in the internal carotid artery and basilar artery varies in the different 
phases of the heart cycle. In this population, blood flow was measured in 16 
phases of a complete heart cycle, where systole was defined as the 3 phases of 
highest flow (phase 13, 14 and 15) and diastole was defined as the 3 phases of 
lowest flow through the artery (phase 10, 11 and 12). Mean wall shear stress 
(MWSS; the mean of the 16 phases of the heart cycle), systolic wall shear stress 
(SWSS; the mean of the 3 phases of highest flow) and diastolic wall shear stress 
(DWSS; the mean of the 3 phases of lowest flow) were all used as outcome 
parameters in this study. These wall shear stress measures have been validated126 
and previously used in elderly patients suffering from vascular disease.127
Statistical Analysis
The categorical variable ‘sex’ was analyzed using a χ2 test. Differences in ‘age’ 
and ‘MMSE’ were analyzed using analysis of variance (ANOVA) with post-hoc 
Bonferroni tests. Group differences in WSS were assed using logistic regression 
corrected for age and sex. Associations between the WSS parameters and MMSE 
were calculated using linear regression models corrected for age and sex. The 
level of significance was set at p < 0.05. 
Results
Demographic characteristics of all subjects are shown in table 5.1. AD patients 
had a lower MMSE score than MCI patients and subjects with normal cognition. 
There were no differences in age and sex between the groups. In the carotid 
arteries, the MWSS, DWSS and SWSS were all lower for AD patients compared 
to control subjects (p < 0.001) (table 5.2). The same was found for MCI patients 
compared to control subjects (p < 0.01 for MWSS and DWSS; p < 0.05 for 
SWSS). No significant differences existed between MCI and AD patients when 
comparing these parameters. In the basilar artery, DWSS was the only parameter 
found to be significantly different between control subjects and MCI or AD 
patients (p < 0.05). 
Sensitivity, specificity, positive predictive value and negative predictive value of 
wall shear stress measures as a diagnostic test differentiating controls from MCI 
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Table 5.3. Sensitivity, specificity, positive predictive value and negative predictive value 
of wall shear stress measures as a diagnostic test differentiating controls from MCI and 
AD patients.
Sensitivity Specificity + PV - PV
MCI Patients
Carotid arteries
MWSS 0.66 0.79 0.87 0.52
DWSS 0.83 0.60 0.81 0.63
SWSS 0.58 0.76 0.84 0.46
Basilar arteries
MWSS 0.54 0.86 0.89 0.46
DWSS 0.93 0.57 0.82 0.80
SWSS 0.69 0.81 0.89 0.54
AD Patients
Carotid arteries
MWSS 0.91 0.52 0.67 0.85
DWSS 0.85 0.57 0.68 0.79
SWSS 0.84 0.51 0.64 0.75
Basilar arteries
MWSS 0.67 0.77 0.75 0.69
DWSS 0.93 0.52 0.67 0.88
SWSS 0.73 0.61 0.67 0.69
+ PV = Positive predictive value
- PV = Negative predictive value
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or AD patients are displayed in table 5.3 . This table shows a good sensitivity 
and a good-to-moderate to good specificity differentiating MCI and AD subjects 
from control subjects. 
WSS parameters for the carotid artery were associated with MMSE (corrected 
for age and sex): MWSS: B = 6.02 (SE = 1.72), β = 0.27, p < 0.001; DWSS: B = 
6.17 (SE = 2.20), β = 0.22, p < 0.01; SWSS: B = 3.10 (SE = 1.09), β = 0.22, p < 
0.01. Parameters for the basilar artery, MWSS: B = 6.69 (SE = 2.56), β = 0.28, p 
< 0.05 and SWSS: B = 3.82 (SE = 1.72), β = 0.23, p < 0.05, were also found to be 
associated with the MMSE.
Discussion
The most important finding of this study was that WSS is significantly lowered in 
both patients suffering from MCI or AD. Furthermore, WSS correlated strongly 
with global cognition. 
Vascular pathology is increasingly seen as a factor contributing to the 
development of AD. The Medical Research Council Cognitive Function and 
Aging Study showed that most demented patients suffered from mixed disease 
as they showed both Alzheimer-type and vascular pathology.9 This vascular 
pathology is also thought to influence cognitive functioning in the earliest 
stages of AD and therefore might also contribute to MCI.22 With this in mind, 
we hypothesized that this vascular pathology could be directly detected in the 
large arteries contributing to the cerebral circulation of MCI and AD patients by 
means of WSS measurements. This hypothesis was confirmed by the finding of 
lower WSS parameters correlating with cognition in these patient groups. 
Mechanical stresses on the arterial wall have been shown to participate in the 
pathogenesis of atherosclerosis with WSS being one of the most important factors 
involved.128-130 Gnasso et al.112;131 observed that WSS significantly decreases with 
increasing atherosclerosis severity and it has been demonstrated that low WSS 
is associated with intima-media thickness. Furthermore, WSS is associated with 
a large number of cardiovascular risk factors and WSS might offer an unique 
explanation for the effects produced by these different risk factors. 
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There are contradictions between studies regarding which WSS parameter is 
associated with flow mediated dilatation.132-135 As it remains unclear which WSS 
parameter is the most clinically relevant, we used all 3 WSS parameters in this 
study. The MWSS, averaged over the heart cycle, the SWSS and DWSS were all 
lower in AD and MCI patients in the carotid artery. In the basilar artery, only 
DWSS was found to differ between groups. This might indicate that the DWWS 
is the most sensitive parameter for detecting vascular pathology. 
One of the major strengths of this study is the robust WSS measurement method 
which required minimal manual interference. Potential limitations include the 
clinical diagnoses that were used for AD and MCI.48;49 Especially with respect 
to MCI, there is a lack of agreement between criteria. We used the criteria for 
amnestic MCI as proposed by Petersen et al.49 This may have resulted in an 
underestimation of the number of MCI patients, as memory is not the first 
failing cognitive domain in all elderly people. However, the application of the 
Petersen criteria resulted in the inclusion of a MCI patient group highly suitable 
for investigating the earliest changes in AD. Furthermore, the sample size of 
subjects in each of the 3 groups is small. 
Future studies could benefit from a longitudinal design. With the cross-sectional 
design of this study it is not clear whether reduced WSS precedes cognitive 
impairment, MCI, or AD. Future studies should also validate our findings in a 
non-referral population. 
To our knowledge, this is the first study to investigate WSS parameters in AD and 
MCI. In the present study we demonstrate that the hemodynamic conditions 
of the carotid and basilar arteries are worse in both MCI and AD compared to 
controls. In addition, the WSS parameters were found to correlate strongly with 
cognition. Therefore, this study adds to the growing body of evidence for an 
important role for vascular pathology in the development of AD.
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Abstract
Background
To define the cardiovascular risk factors for cerebral microbleeds and to 
investigate the relationship between microbleeds on the one hand, and the 
volume of agerelated white matter hyperintensities (WMH) and atrophy on the 
other in an elderly population. 
Methods
Four hundred and thirty-nine elderly subjects (age range: 72–85; mean: 77) 
suffering from vascular disease or at high risk for developing this condition 
were included in this study. For each subject the number and localization of the 
microbleeds was recorded. 
Results
The prevalence of microbleeds in this study was 24%. We found age and a history 
of hypertension to be risk factors for microbleeds. After regional subdivision 
systolic blood pressure was found to be a risk factor for microbleeds located 
in the basal ganglia. A history of hypertension was more prevalent in patients 
with cortico-subcortical and basal ganglia microbleeds. Magnetic resonance 
imaging risk factors associated with one or more microbleeds were total WMH 
volume, subcortical WMH volume, and periventricular WMH volume. Total 
WMH volume and periventricular WMH volume were risk factors for cortico-
subcortical microbleeds and basal ganglia microbleeds. 
Conclusion
A high prevalence of microbleeds was found in a population of patients 
suffering from vascular disease or at high risk for developing this condition. Age, 
hypertension and WMH were the most important risk factors for microbleeds, 
especially when located in the corticosubcortial junction or in the basal ganglia.
Risk Factors for Cerebral Microbleeds in the Elderly
67 
Introduction
Microbleeds are commonly found on gradient-echo T2-weighted brain images 
of elderly individuals. Two previous studies determined the prevalence of 
microbleeds in the normal population. Roob et al.136 found a prevalence of 6.4%, 
whereas Jeerakathil et al.137 reported a prevalence of 4.7%. Furthermore, both 
studies reported an association with age and male sex. 
The clinical relevance of microbleeds has primarily been discussed in the light of 
cerebral hemorrhage and ischemic stroke since it is known that the prevalence 
of microbleeds is high in both conditions.138 In ischemic stroke, microbleeds 
are more commonly noted in patients with small vessel disease ischemic stroke 
than in patients suffering from large vessel stroke (atherothromboembolic 
or cardioembolic), whereas in hemorrhagic stroke, microbleeds are more 
prevalent in recurrent than first-ever hemorrhagic stroke.23;139 In both cerebral 
hemorrhage and ischemic stroke microbleeds are thought to be a risk 
factor for respectively recurrent intracerebral hemorrhage and hemorrhagic 
transformation140-143 although a recent study by Fiehler et al.144 suggested that 
the risk estimate of hemorrhage in the presence of microbleeds is unlikely to 
exceed the benefit of thrombolytic treatment in MRI-selected patients. The 
assumption of microbleeds reflecting a bleeding-prone micrangiopathy has also 
been confirmed by histopathological studies identifying cerebral microbleeds 
as small extravasations of blood accompanying microangiopathy of different 
origins.145;146 The clinical significance of microbleeds has been further stressed 
by Werring et al.147, who showed that microbleeds are not clinically silent but 
show an independent association with cognitive dysfunction. 
Data on risk factors for microbleeds in the general population are scarce. In a 
univariate analysis, Roob et al.136 found hypertension, lacunes, and white matter 
hyperintensities (WMH) to be risk factors for microbleeds. Jeerakathil et al.137 
found blood pressure, brain volume, and WMH volume to be risk factors but 
this association disappeared after correction for age and sex. The main limitation 
of both studies was the low statistical power caused by the low prevalence of 
microbleeds and the relatively small study groups. Therefore, the suggestion was 
made that future studies would benefit from a focus on larger populations and 
in particular those with a high prevalence of microbleeds, such as people older 
than 75 years. 
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The purpose of this study is twofold. First, to define the cardiovascular risk factors 
for microbleeds. Second, to investigate the association between microbleeds 
and radiological signs of neurodegeneration as expressed by an increased WMH 
volume, increased cerebral atrophy and decreased total cerebral blood flow. In 
the present study all patients suffered from cardiovascular disease or were at high 
risk for developing this condition and are therefore perfectly suited to investigate 
the risk factors for microbleeds.
Methods
Patients
Patients were included from the nested MRI substudy of the PROspective 
Study of Pravastatin in the Elderly at Risk (PROSPER) who were recruited 
from the general population. Inclusion criteria for this study were: men or 
women aged 70–82 years with a total cholesterol of 4.0–9.0 mmol/l; or stroke, 
transient ischemic attack, myocardial infarction, arterial surgery, or amputation 
for vascular disease; or at least one of the following risk factors for vascular 
disease: current smoker; hypertension, or currently receiving drug treatment; or 
known diabetes mellitus or fastening blood glucose > 7 mmol/l. Of the subjects 
included in this study 43.1% suffered from symptomatic vascular disease (‘any 
vascular disease’). However, these subjects did not experience symptoms < 6 
months before entering the study. Exclusion criteria have been described in detail 
elsewhere.108 MRI data, including dual and fluid-attenuated inversion recovery 
(FLAIR) images for the gray matter, white matter, and WMH segmentation 
and a susceptibility-weighted scan for microbleed score, was available for 439 
subjects. The demographic characteristics of the study population are displayed 
in table 6.1.
MRI Scanning
All imaging was performed on an MR system operating at a field strength of 
1.5 T (Philips Medical Systems, Best, The Netherlands). Dual fast spin echo 
[repetition time (TR) = 3,000 ms; echo time (TE) = 27/120 ms; flip angle = 
90°; slice thickness = 3 mm; 48 slices; no interslice gap; field of view (FOV) = 
220 x 220 mm; matrix = 256 x 204], FLAIR (TR = 8,000 ms; TE = 100 ms; flip 
angle = 90°; slice thickness = 3 mm; 48 slices; no interslice gap; FOV = 220 x 176 
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mm; matrix = 256 x 153) and susceptibility weighted images (multislice gradient 
echo sequence; TR = 2593 ms; TE = 48 ms; flip angle = 60°; slice thickness = 6 
mm; 22 slices; interslice gap = 6 mm; whole brain coverage; FOV = 220 x 198 
mm; matrix = 256 x 176) were obtained from all subjects. In addition, single 
slice phase contrast MR angiography (TR/TE = 16/9 ms; flip angle = 7.5°; slice 
thickness = 5 mm; FOV = 250; RFOV = 75%; scan percentage = 80%; matrix = 
256; 8 signal averages) with a velocity encoding of 100 cm/s was used for flow 
measurements.109 The scans were performed in a plane perpendicular to the 
left and right internal carotid artery and the vertebral arteries, at the level of the 
vertical segment of the petrous portion of the internal carotid artery.
MRI Analysis: Microbleeds
All MRI scans were read in consensus by 2 experienced raters (A.C.G.M.v.E. and 
M.A.v.B.), who were blinded to the clinical history. Microbleeds were defined 
as focal areas of signal loss on T2-weighted images that increased in size on 
the T 2 -weighted gradient echo planar images (‘blooming effect’). In this way, 
microbleeds were differentiated from areas of signal loss based on vascular flow 
void. Areas of symmetric hypointensity in the basal ganglia likely to represent 
calcification or nonhemorrhagic iron deposits were disregarded. The location, 
number, and size of microbleeds were recorded. For each subject the number 
and localization (cortico-subcortical junction, deep white matter, basal ganglia 
and infratentorial) of the microbleeds was recorded.
MRI Analysis: White Matter Hyperintensities and Atrophy
Segmentation of WMH, intracranial volume, and brain parenchyma volume 
was performed automatically using Software for Neuro-Image Processing 
in Experimental Research (SNIPER)65, an in-house-developed program for 
image processing. This segmentation was done on the T2-weighted and FLAIR 
images. Hyperintensities connected to the lateral ventricles were labeled as 
periventricular WMH. Hyperintensities not connected to the lateral ventricles 
were labeled as deep WMH.148 The volume of periventricular WMH and deep 
WMH was calculated automatically. All measurements were performed blinded 
to subject identity, age, and sex. A measure reflecting atrophy was calculated using 
the equation: atrophy (%) = [(intracranial volume – parenchymal volume)/
intracranial volume] x 100%.44;149 
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Table 6.1. Demographic characteristics.
Continuous variates mean (SD) median 25 perc. 75 perc.
Age, years 77 (3) 77 74 80
Systolic blood pressure, mmHg 157 (21) 157 141 171
Diastolic blood pressure, mmHg 86 (11) 85 80 92
Total cholesterol, mmol/L 5.77 (0.9) 5.70 5.17 6.30
LDL cholesterol mmol/L 3.92 (0.7) 3.90 3.47 4.37
HDL cholesterol, mmol/L 1.24 (0.3) 1.20 1.00 1.42
Triglycerides, mmol/L 1.49 (0.6) 1.32 1.05 1.77
Categorical variates n (%)
Male gender 248 (55.9)
Current smoker 89 (20.3)
History of diabetes* 66 (15.0)
History of hypertension* 283 (64.5)
History of myocard infarction* 52 (11.8)
History of any vascular disease* 189 (43.1)
Stroke* 190 (43.3)
* = no symptoms <6 months before entering the study
LDL = low density lipoprotein
HDL = high density lipoprotein
Table 6.2. MRI characteristics.
mean (SD) median 25 perc. 75 perc.
Parenchyma volume, mL 1014 (101) 1016 941 1080
Atrophy, % 27.2 (3.5) 27.1 25.2 29.3
Total WMH volume, mL 7.17 (10.8) 2.85 0.86 9.68
Subc. WMH volume, mL 1.55 (2.1) 0.74 0.23 1.96
Periv. WMH volume, mL 5.62 (9.2) 2.01 0.46 6.93
Total CBFa, min-1 .50 (.09) 0.50 0.44 0.55
a = cerebral blood flow, normalized for parenchyma volume
Subc. = subcortical
Periv. = periventricular
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MRI Analysis: Total Cerebral Blood Flow
For assessment of total cerebral blood flow, single slice phase contrast MR 
images109 were analyzed using the software package FLOW®.110 For this analysis 
a region of interest was manually drawn around the left and right internal carotid 
and the right and left vertebral arteries in the magnitude image by one observer 
(A.C.G.M.v.E.). The flow in these four vessels was summed giving the total 
cerebral blood flow. Flow measurements were corrected for parenchyma volume. 
Statistical Analysis
All continuous parameters were dichotomized around the median. Odds ratios 
(OR) were calculated with corresponding 95% confidence interval (CI). All 
odds ratios were corrected for age and sex. Furthermore, odds ratios for a given 
anatomical region were corrected for the presence of microbleeds in the other 
anatomical regions.
 
Results
The prevalence of microbleeds was 24% (106/439). The mean number of 
microbleeds per subject was 0.64 (range: 0 - 22). No difference in prevalence 
of microbleeds was found between subjects with symptomatic vascular disease 
(‘any vascular disease’) (mean number of microbleeds: 0.52; range: 0 - 13) and 
asymptomatic patients (mean number of microbleeds: 0.73; range 0 - 22; p = 
0.95). In total we found 282 microbleeds of which 52% (147 / 282) were located 
cortico-subcortical, 14% (39 / 282) in the deep white matter, 18% (50 / 282) in the 
basal ganglia, and 16% (46 / 282) infratentorially. Demographic characteristics 
are described in table 6.1. Table 6.2 displays the MRI characteristics. 
Table 6.3 shows the odds ratios for the different cardiovascular risk factors 
associated with microbleeds. We found age (OR: 1.59; 95% CI: 1.01 - 2.50) and 
a history of hypertension (OR: 2.15; 95% CI: 1.29 - 3.59) as risk factors for 
microbleeds. None of the other parameters was associated with the presence of 
microbleeds. 
The MR abnormalities associated with microbleeds are shown in table 6.4 . Risk 
factors for one or more microbleeds were total WMH volume (OR: 2.66; 95% 
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Table 6.3. Comparison of cardiovascular risk factors in subjects with and without 
cerebral microbleeds.
Without 
CMBs
(n = 333)
With CMBs
(n = 106) OR (CI 95%)
Age >77 y 169 (50.8%) 65 (61.3%) 1.59 (1.01 – 2.50)
Systolic blood pressure >157 mmHg 167 (50.2%) 52 (49.1%) 0.95 (0.61 – 1.47)
Diastolic blood pressure >85 mmHg 158 (47.4%) 54 (50.9%) 1.19 (0.77 – 1.85)
Total cholesterol >5.70 mmol/L 163 (48.9%) 55 (51.9%) 1.20 (0.75 – 1.91)
LDL cholesterol >3.90 mmol/L 165 (49.5%) 51 (48.1%) 0.98 (0.62 – 1.55)
HDL cholesterol >1.20 mmol/L 168 (50.5%) 56 (52.8%) 1.12 (0.71 – 1.76)
Triglycerides >1.49 mmol/L 166 (49.8%) 50 (47.2%) 0.90 (0.58 – 1.41)
Male gender 189 (55.9%) 62 (58.5%) 1.17 (0.75 – 1.84)
Current smoker 71 (21.3%) 18 (17.0%) 0.77 (0.43 – 1.38)
History of diabetes 54 (16.2%) 12 (11.3%) 0.67 (0.34 – 1.38)
History of hypertension 203 (61.0%) 80 (75.5%) 2.15 (1.29 – 3.59)
History of myocard infarction 41 (12.3%) 11 (10.4%) 0.79 (0.39 – 1.61)
History of any vascular disease 143 (42.9%) 46 (43.4%) 0.96 (0.61 – 1.51)
Stroke 138 (41.4%) 53 (49.1%) 1.30 (0.83 –2.02)
LDL = low density lipoprotein
HDL = high density lipoprotein
Table 6.4. Comparison of MR risk factors in subjects with and without cerebral 
microbleeds.
Without CMBs With CMBs OR (CI 95%)
Parenchyma volume > 1016 mL 163 (48.9%) 53 (50.0%) 0.44 (0.17 – 1.16)
Atrophy > 27.1% 164 (49.2%) 51 (48.1%) 0.84 (0.53 – 1.34)
Total WMH volume > 2.85 mL 147 (44.1%) 72 (67.9%) 2.66 (1.66 – 4.26)
Subc. WMH volume > .74 mL 157 (47.1%) 66 (62.3%) 1.85 (1.17 – 2.93)
Periv. WMH volume > 2.01 mL 148 (44.4%) 72 (67.9%) 2.65 (1.66 – 4.24)
Total CBFa > 0.50 min-1 167 (50.2%) 45 (52.3%) 0.59 (0.22 – 1.56)
a = cerebral blood flow, normalized for parenchyma volume
Subc. = subcortical
Periv. = periventricular
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CI: 1.66 - 4.26), subcortical WMH volume (OR: 1.85; 95% CI: 1.17 - 2.93) and 
periventricular WMH volume (OR: 2.65; 95% CI: 1.66 - 4.24). No significant 
association was found with either atrophy or total cerebral blood flow. 
After the subdivision in different regions of the brain, systolic blood pressure was 
found to be a risk factor for microbleeds located in the basal ganglia (OR: 6.39; 
95% CI: 1.83 - 22.29). A history of hypertension was more prevalent in patients 
with cortico-subcortical junction (OR: 1.92; 95% CI: 1.03 - 3.58) and basal 
ganglia microbleeds (OR: 10.02; 95% CI: 1.25 - 88.66). No risk factors were 
associated with microbleeds located in the deep white matter or infratentorially 
(table 6.5).
Total WMH volume and periventricular WMH volume were found to be risk 
factors after regional subdivision for cortico-subcortical microbleeds (OR: 
1.88; 95% CI: 1.07 - 3.33 and OR: 2.09; 95% CI: 1.18 - 3.72) and basal ganglia 
microbleeds (OR: 4.34; 95% CI: 1.20 - 15.71 and OR: 4.41; 95% CI: 1.22 - 
15.95). Again, no risk factors were found for microbleeds located in the deep 
white matter or infratentorially (table 6.6).
Discussion
In this study we found that the prevalence of microbleeds is 24% (106 / 439) 
in an elderly population of patients suffering from vascular disease or at high 
risk for developing this condition. Age and a history of hypertension emerged as 
most important cardiovascular risk factors for the presence of microbleeds. On 
MRI, microbleeds were associated with a higher volume of both periventricular 
WMH and deep WMH and consequently a higher total WMH volume. After 
subdivision in anatomical regions we found systolic blood pressure to be a risk 
factor for microbleeds located in the basal ganglia. A history of hypertension 
was associated with microbleeds located in the cortico-subcortical junction and 
in the basal banglia. Furthermore, patients suffering from cortico-subcortical 
junction microbleeds or microbleeds located in the basal ganglia had a higher 
total and periventricular WMH load.
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The prevalence of microbleeds (24%) in this population of patients suffering 
from vascular disease or at high risk for developing this condition was higher 
than the 3.7 - 8.5% previously found in populations without cardiovascular risk 
factors.138 However, the prevalence in this population is lower than in patients 
suffering from ischemic cerebrovascular disease (40%).138 Microbleeds were 
most frequently found on the cortical subcortical junction. Some previous 
studies investigating the healthy population also found the cortico-subcortical 
junction to be preferential location for microbleeds whereas others found a 
higher prevalence of microbleeds located in the deep structures.136;137;150 A 
study by Lee et al.151 investigating microbleeds in 129 hypertensive patients 
found more microbleeds in the cortico-subcortical region. As the prevalence of 
hypertension is high in our population this might explain the large number of 
cortico-subcortical microbleeds in our study. 
In previous studies hypertension has not consistently been found to be associated 
with microbleeds. One study found an association between microbleeds and 
hypertension which disappeared after the correction for age and sex137, while 
other studies with a similar finding did not take the effect of age and sex into 
account.136;150 In patients suffering from ischemic cerebrovascular disease 
microbleeds were associated with chronic hypertension in some studies, but 
others did not confirm this association.138 In our study we found that a history 
of hypertension is a risk factor for microbleeds after correction for age and sex. 
When the different anatomical regions were analyzed separately, a history of 
hypertension was found to be a risk factor for microbleeds located in the cortico-
subcortical junction and basal ganglia. Furthermore, systolic and diastolic blood 
pressure were found to be risk factors for microbleeds in the basal ganglia. This 
association between hypertension and the presence of microbleeds in the basal 
ganglia might be analogous to the situation of intracerebral hematomas, which 
are most commonly observed in the basal ganglia.152;153 
We found a correlation between microbleeds and both total and periventricular 
WMH volume. Similar to hypertension, WMH were only associated with 
microbleeds located in the basal ganglia and the cortico-subcortical junction. 
This might suggest that cerebral microbleeds in the basal ganglia and the cortico-
subcortical junction and WMH share hypertension as a common etiology. 
Regarding stroke, we did not find a higher prevalence of stroke in the patients 
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with microbleeds. This might be explained by the fact that the entire population 
studied had a variety of risk factors for stroke whereas previous studies mainly 
compared a stroke population with a healthy population (with no or low vascular 
risk factors), or determined the prevalence of microbleeds in a stroke population 
only. We are aware that the selection of patients suffering from or at high risk for 
developing vascular disease does not give a reflection of the prevalence of and 
risk factors for microbleeds in the normal aging population (although ‘normal 
aging’ is hard to define). However, the population used in this study is at high 
risk for the development of clinical stroke. Therefore, the knowledge of risk 
factors for and prevalence of microbleeds in this type of population is highly 
important as microbleeds are most likely to be clinically relevant in this specific 
population. Hence, future studies investigating the clinical relevance of these 
lesions will focus on these ‘high-risk’ patients. The large size of the sample of 
individuals that were included, and the high prevalence of microbleeds in our 
study, based on the selection criteria we used, allowed us to assess the risk factors 
for the lesions without the risk of type II errors. Furthermore, it allowed analysis 
of risk factors for microbleeds in the separate anatomical regions. 
In summary, we found a high prevalence of microbleeds in a population of patients 
suffering from vascular disease or at high risk for developing this condition. Age, 
hypertension and WMH were the most important risk factors for microbleeds, 
especially when located on the cortico-subcortical junction and basal ganglia.
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Abstract
Objectives
Cerebral microbleeds (MBs) are an important indicator of cerebral small-vessel 
disease, and their prevalence increases with increasing age. Little is known about 
the functional consequences of MBs in the aging population. In this study we 
investigated whether the presence and location of MBs are associated with 
cognition in the PROSPER study.
Methods
For 439 subjects the number and location (cortico-subcortical, deep white 
matter, basal ganglia, and infratentorial) of the MBs was recorded. Difference in 
cognitive performance between subjects with and without MBs was calculated 
by entering the variables sex, age, white matter hyperintensity volume, infarction, 
and MBs in a linear mixed model. Differences in cognition between subjects 
with and without one or more MBs at different anatomic locations were assessed 
using the same model. 
Results
We found that after correction for sex, age, white matter hyperintensity volume, 
and infarction, subjects with infratentorial MBs had a significantly lower score 
on the Immediate Picture-Word Learning test, Delayed Picture-Word Learning, 
and Instrumental Activities of Daily Living.
Conclusions
Our data demonstrate that in elderly individuals at increased vascular risk, 
infratentorial MBs are associated with loss in cognitive functioning.
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Introduction
Cerebral microbleeds (MBs) are a radiologic entity, characterized by discrete 
areas of signal loss based on susceptibility artifacts.154 The histologic substrate 
of these areas are small perivascular deposits of blood breakdown products, 
and in particular hemosiderin.145;146 The prevalence of MBs increases with age, 
which can be explained by the increased prevalence of arteriolosclerosis and in 
particular CAA in the elderly, with estimated prevalences ranging from 4.5% to 
7.7% in elderly from the general population.23 
There is increasing awareness that MBs are a relevant finding as they are strongly 
associated with intracerebral hemorrhage and ischemic stroke. In stroke cohorts 
MBs are more prevalent in patients with recurrent stroke than in patients with 
first-ever stroke23, indicating that MBs are associated with both presence and 
progression of cerebrovascular disease. Furthermore, data suggest that MBs 
predict subsequent recurrent stroke, both hemorrhagic and ischemic.141;150;155;156 
Although MBs have become an established radiologic marker for the presence 
of small-vessel disease in vivo, little is known about the functional consequences 
of the presence and location of MBs. In some recent studies in small populations 
of patients with distinct cerebrovascular pathologies147;157, and in a preliminary 
study on neurologically healthy subjects158, associations have been found 
between MBs and cognitive decline. The aim of the present study is to assess 
whether the presence and location of MBs are associated with cognitive loss at 
old age in a population of elderly with an increased vascular risk (the PROSPER 
study).
Methods
Standard protocol approvals, registrations, and patient consents
The PROSPER study had ethics review board approval of all locations and 
written informed consent of all participants. In addition, the Leiden University 
Medical Centre institutional ethics review board approved the protocol for the 
prospective magnetic resonance (MR) study and subsequent retrospective 
analyses. Moreover, all participants gave written informed consent. Participants 
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Table 7.1. Demographic characteristics of the study population.
Continuous variables means (SD)
Age, y 77 (3)
Systolic blood pressure, mm Hg 157 (21)
Diastolic blood pressure, mm Hg 86 (11)
Total cholesterol, mmol/L 4.81 (0.98)
LDL cholesterol, mmol/L 3.05 (0.89)
HDL cholesterol, mmol/L 1.29 (0.36)
Triglycerides, mmol/L 1.40 (0.69)
Body Mass Index 26.6 (3.6)
WMH volume, mL 7.2 (11)
Categorical variables n (%)
Male gender 248 (55.9)
Current smoker 89 (20.3)
History of diabetes 66 (15.0)
History of hypertension 283 (64.5)
History of myocardial infarction 52 (11.8)
History of any vascular disease 189 (43.1)
Infarct* 190 (43.3)
Abbreviations: HDL = high-density lipoprotein; LDL = low-density lipoprotein; WMH 
= white matter hyperintensity. * = no symptoms <6 months before entering the study
of this MR study also agreed with future retrospective analysis of their MR data 
for research purposes.
Patients
Subjects were drawn from the nested MRI substudy of the Prospective Study of 
Pravastatin in the Elderly at Risk (PROSPER). Inclusion criteria for this study 
were men or women aged 70 - 82 years; total cholesterol 4.0 - 9.0 mmol/L; stroke, 
TIA, myocardial infarction, arterial surgery, or amputation for vascular disease >6 
months before study entry; ≥1 of the following risk factors for vascular disease: 
current smoker, hypertension, currently receiving drug treatment, known 
diabetes mellitus or fastening blood glucose >7 mmol/L. Exclusion criteria have 
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been described in detail elsewhere.108 Of the 1,100 eligible Dutch participants 
in the PROSPER study, the last consecutive 646 subjects were included in the 
MRI substudy. From these original 646 subjects, 92 dropped out of the study 
for the following reasons. At baseline MRI, 7 subjects were claustrophobic and 
2 subjects had no MRI owing to technical problems. At the time of follow-up, 
40 subjects had died, 3 subjects had a contraindication for MR scanning, 6 had 
withdrawn informed consent, and 34 subjects refused a second MRI because 
of claustrophobia or illness. In total, 554 subjects underwent MRI at follow-up. 
The GRE T2* for the analysis of MBs was introduced to the scan protocol during 
follow-up and the last 451 consecutive subjects underwent GRE T2* scanning. 
Twelve subjects dropped out due to incomplete MRI data are movement 
artifacts. This resulted in a study population of 439 subjects. The demographic 
characteristics of this study population are shown in table 7.1. 
Measures of cognitive functioning
Cognitive functioning was assessed using a battery of neuropsychological tests. 
The battery was designed to assess global cognitive functioning with a specific 
focus on memory and executive functioning. Global cognitive functioning 
was tested using the Mini-Mental State Examination (MMSE).47 Memory 
functioning was estimated with the Picture Word Learning Test (PWLT).159 
Tests of executive functioning and attention included the Letter Digit Coding 
Test (LDCT) and the abbreviated Stroop Color Word Test.160 The PWLT was 
derived from the Fifteen Words Test161, originally described by Rey. In this test, 
15 pictures are presented sequentially to the subject, who is asked to recall as 
many objects as possible. This process is repeated 3 times and, after 20 minutes, 
delayed recall is tested. The LDCT we used is a modification of the procedurally 
identical Symbol Digits Modalities Test, used to measure the speed of processing 
of general information.159 The Stroop test has often been used to test selective 
attention and speed of processing; subjects are asked to successively read 
sheets with 1) color names, 2) colored patches, and 3) color names printed in 
incongruously colored ink. In the latter, subjects have to name the color of the 
word, not the word itself. In our analyses we used the average number of items 
reported correctly in the 3 immediate recall conditions (immediate PWLT), the 
number of items correctly generated in the delayed recall condition (delayed 
PWLT), the number of correct digits for the LDCT, and time to complete the 
color interference section of the Stroop test. The Barthel Index was used as a 
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measure of activities of daily living (ADL).162 The Barthel Index gives a score out 
of 20, principally concerned with physical aspects of disability. The instrumental 
activities of daily living (IADL) measures activities related to independent 
living and include preparing meals, managing money, shopping for groceries 
or personal items, performing light or heavy housework, and using a telephone. 
The maximum IADL score is 27.
MRI scanning
All imaging was performed on an MR system operating at a field strength of 
1.5 Tesla (Philips Medical Systems, Best, the Netherlands). Dual fast spin echo 
(repetition time [TR] = 3,000 msec; echo time [TE] = 27/120 msec; flip angle 
= 90°; slice thickness = 3 mm; 48 slices; no interslice gap; field of view [FOV] 
= 220 x 220 mm; matrix = 256 x 204), fluid-attenuated inversion recovery 
(FLAIR) (TE = 100 msec; TR = 8,000 msec; flip angle = 90°; slice thickness = 3 
mm; 48 slices; no interslice gap; FOV = 220 x 176 mm; matrix = 256 x 153), and 
GRE T2* (multislice gradient echo sequence; TE = 48 msec; TR = 2,593 msec; 
flip angle = 60°; slice thickness = 6 mm; 22 slices; interslice gap = 6 mm; whole 
brain coverage; FOV = 220 x 198 mm; matrix = 256 x 176) were obtained from 
all subjects. 
MRI analysis: MB. 
All MRI scans were read in consensus by 2 experienced raters (A.C.G.M.v.E. and 
M.A.v.B.) who were blinded to the subjects’ clinical history. MBs were defined as 
focal areas of signal loss on T2*-weighted gradient echo pulse sequence (“bloom-
ing effect”) that are invisible or smaller on T2-weighted MRI.154 In this way, MBs 
were differentiated from areas of signal loss based on vascular flow voids. Areas of 
symmetric hypointensity of the globus pallidus likely to represent calcification 
or nonhemorrhagic iron deposits were ignored. To differentiate MBs from other 
intra-axial lesions with a hemorrhagic component (such as hemorrhagic infarcts 
or larger hematomas), only areas of signal loss that are not locally associated 
with other abnormalities were considered MBs. MBs were discriminated from 
cavernomas by the presence of the typical popcorn-shaped area of high signal 
centrally within the area of signal void in the latter. Only spots with hemosiderin 
characteristics without any structure within these spots were considered MBs. 
For each subject the number and location (cortico-subcortical, deep white 
matter, basal ganglia, and infratentorial) of the MBs was recorded. Examples of 
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T2*-weighted gradient echoplanar MRI showing MBs at the different anatomic 
regions are shown in figure 7.1. 
MRI analysis: White matter hyperintensities and infarcts. 
Segmentation of white matter hyperintensities (WMH) volume was performed 
automatically using Software for Neuro-Image Processing in Experimental 
Research (SNIPER), an in-house developed program for image processing.65 
This segmentation was based on the T2-weighted and FLAIR images. Infarcts 
were defined as parenchymal defects seen on FLAIR images with the same 
signal intensity as CSF and a surrounding rim of high signal intensity following 
a vascular distribution. Patients did not suffer from symptoms at least 6 months 
before study entry. 
Figure 7.1. T2*-weighted gradient echoplanar images showing an example of a 
microbleed located cortico-subcortically (A), in the deep white matter (B), in a basal 
ganglia (C), and an example of a microbleed located infratentorally (D).
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Statistical analysis. 
SPSS for Windows (release 10.0; SPSS, Chicago, IL) was used for data analysis. 
Differences in cognitive performance between subjects with and without MBs 
were first compared using t-tests. After this we entered the variables sex, age, 
WMH volume, infarcts, and MBs in a linear regression model to asses whether the 
observed differences were still found after correction for possible confounders. 
Differences in cognition between subjects with or without one or more MBs at a 
given anatomic location were assessed using the same model. First we compared 
subjects with MBs at a given anatomic location with the rest of the population 
(including subjects with MBs at different locations) using t-tests. After that, the 
variables sex, age, WMH volume, infarcts, cortico-subcortical MBs, deep white 
matter MBs, basal ganglia MBs, and infratentorial MBs were entered in a linear 
regression model to correct for possible confounders. The level of statistical 
significance was set at p < 0.05. Interrater and intrarater reliability was analyzed 
using Cohen κ. To assess intrarater reliability, the location of MBs was rated 
twice in 50 brains with an interval of 4 weeks.
Results
The interrater reliability (cortico-subcortical: κ = 0.90; deep white matter: κ = 
0.81; basal ganglia: κ = 0.88; infratentorial: κ = 0.81) and intrarater reliability 
(cortico-subcortical: κ = 0.95; deep white matter: κ = 0.91; basal ganglia: κ 
= 0.88; infratentorial: κ = 0.86) for the detection of MBs was excellent for all 
anatomic locations investigated in this study. 
A total of 282 MBs were found in this study. The prevalence of MBs in the 
complete study population was 24% (106 / 439) with a mean number of MBs 
per subject of 0.64 (range 0 - 22). The mean number of MBs per subject in the 
group of patients with MBs was 2.66. In 49% of patients with MBs, MBs were 
multiple. 
When studying the distribution of MBs over the different anatomic regions, 
147 MBs were located cortico-subcortically, 39 in the deep white matter, 50 in 
the basal ganglia, and 46 infratentorially. Of the subjects with MBs, 71% had 
MBs located cortico-subcortically, 25% of the subjects had MBs located in the 
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deep white matter, 19% had MBs located in the basal ganglia, and 24% had MBs 
located infratentorially. 
The distribution over the different cerebral lobes of the MBs that could be 
attributed a specific cerebral lobe (cortico-subcortical and deep white matter 
MBs) was as follows: 41 MBs were located in the frontal lobe, 55 were located 
in the parietal lobe, 42 were located in the temporal lobe, and 48 were located in 
the occipital lobe. 
To investigate the influence of MBs on cognitive functioning, we first compared 
subjects without MBs with subjects with one or more MBs in any given 
anatomic location, indicating no differences between these 2 groups in the 
crude analysis and after correction for possible confounders (table 7.2). After 
the subdivision in the different anatomic areas, no differences in cognition were 
found when comparing patients without and patients with MBs located cortico-
subcortically, in the deep white matter or basal ganglia. However, subjects with 
MBs located infratentorally had a significantly lower score on the Immediate 
PWLT, Delayed Picture-Word Learning, Stroop test, and IADL in the crude 
analysis. No differences were found for the MMSE, Letter Digit Coding Test, 
and Barthel Index. 
After correction for possible confounders, again no differences in cognition were 
found when comparing patients without and patients with MBs located cortico-
subcortically (MMSE: p = 0.92; PWLT immediate: p = 0.41; PWLT delayed 
= 0.20; LDCT: p = 0.66; Stroop: p = 0.80; Barthel Index: p = 0.79; IADL: p = 
0.61), in the deep white matter (MMSE: p = 0.85; PWLT immediate: p = 0.16; 
PWLT delayed = 0.56; LDCT: p = 0.48; Stroop: p = 0.96; Barthel Index: p = 
0.94; IADL: p = 0.72), or basal ganglia (MMSE: p = 0.44; PWLT immediate: p 
= 0.25; PWLT delayed = 0.25; LDCT: p = 0.25; Stroop: p = 0.91; Barthel Index: 
p = 0.94; IADL: p = 0.80). However, the differences in Immediate Picture-
Word Learning test, Delayed Picture-Word Learning, and IADL remained after 
correction for possible confounders (table 7.3). 
The demographic characteristics of subjects with infratentorial MBs are displayed 
in table 7.4. No difference was found for any of these parameters compared to 
subjects without infratentorial MBs.
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Table 7.2. Comparison of cognitive parameters in subjects with and without 
microbleeds. 
Without MBs 
(SE) (n = 333)
With MBs (SE)
(n = 106)
Difference 
(SE) p
Crude Modela
Global Cognitive Functioning
MMSE (points) 28.4 (0.1) 28.5 (0.2) -0.1 (0.2) 0.81
Memory
PWLT immediate (words)
PWLT delayed (words)
10.2 (0.1)
11.2 (0.2)
10.1 (0.2)
11.1 (0.3)
 0.0 (0.2)
0.2 (0.3)
0.93
0.67
Executive Functioning
LDCT (digits/min)
Stroop (seconds)
26.4 (0.4)
56.2 (1.2)
26.4 (0.6)
56.3 (1.9)
 0.0 (0.8)
- 0.5 (2.4)
0.99
0.99
Activities of Daily Living
Barthel Index (points)
IADL (points)
19.4 (0.1)
12.9 (0.1)
19.4 (0.1)
12.8 (0.2)
- 0.0 (0.2)
0.0 (0.2)
0.88
0.83
Adjusted Modelb
Global Cognitive Functioning
MMSE (points) 28.5 (0.1) 28.6 (0.2) -0.1 (0.2) 0.64
Memory
PWLT immediate (words)
PWLT delayed (words)
10.1 (0.1)
11.2 (0.2)
10.2 (0.2)
11.1 (0.3)
-0.1 (0.2)
 0.1 (0.3)
0.81
0.76
Executive Functioning
LDCT (digits/min)
Stroop (seconds)
26.3 (0.4)
56.1 (1.2)
27.0 (0.7)
55.1 (2.1)
-0.7 (0.8)
 1.1 (2.4)
0.43
0.65
Activities of Daily Living
Barthel Index (points)
IADL (points)
19.4 (0.1)
12.9 (0.1)
19.5 (0.1)
12.9 (0.2)
-0.1 (0.2)
0.0 (0.2)
0.79
0.90
Abbreviations: IADL = Instrumental Activities of Daily Living; LDCT = Letter Digit 
Coding Test; MB = microbleed; MMSE = Mini Mental State Examination; PWLT = 
Picture Word Learning Test.
a Crude model: t tests.
b Adjusted model corrected for sex, age, white matter hyperintensity volume, and 
infarction.
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Table 7.3. Comparison of cognitive parameters in subjects with and without 
microbleeds located infratentorally.
Without Infra-
tentorial MBs 
(SE) (n = 414 )
With Infra-
tentorial MBs 
(SE) (n = 25)
Difference 
(SE) p
Crude Modela
Global Cognitive Functioning
MMSE (points) 28.5 (0.1) 28.3 (0.4) -0.1 (0.4) 0.68
Memory
PWLT immediate (words)
PWLT delayed (words)
10.2 (0.1)
11.2 (0.1)
 9.1 (0.5)
 9.8 (0.8)
 1.1 (0.4)
1.4 (0.6)
0.01
0.02
Executive Functioning
LDCT (digits/min)
Stroop (seconds)
26.5 (0.4)
55.7 (1.1)
24.3 (1.3)
64.7 (4.3)
2.2 (1.5)
- 9.0 (4.4)
0.14
0.04
Activities of Daily Living
Barthel Index (points)
IADL (points)
19.5 (0.1)
12.9 (0.1)
19.0 (0.3)
11.5 (0.6)
 - 0.5 (0.3)
 1.4 (0.4)
 0.15
< 0.01
Adjusted Modelb
Global Cognitive Functioning
MMSE (points) 28.7 (0.3) 28.8 (0.4) -0.1 (0.4) 0.87
Memory
PWLT immediate (words)
PWLT delayed (words)
11.0 (0.3)
12.0 (0.4)
 9.8 (0.4)
10.5 (0.6)
1.2 (0.4)
1.6 (0.6)
< 0.01
 0.01
Executive Functioning
LDCT (digits/min)
Stroop (seconds)
28.7 (1.0)
52.7 (3.0)
26.8 (1.6)
60.1 (4.6)
 1.9 (1.6)
-7.4 (4.6)
0.24
0.11
Activities of Daily Living
Barthel Index (points)
IADL (points)
19.6 (0.6)
13.3 (0.3)
19.2 (0.3)
11.8 (0.4)
0.4 (0.3)
1.6 (0.4)
 0.27
< 0.01
Abbreviations: IADL = Instrumental Activities of Daily Living; LDCT = Letter Digit 
Coding Test; MB = microbleed; MMSE = Mini Mental State Examination; PWLT = 
Picture Word Learning Test.
a Crude model: t tests.
b Adjusted model corrected for sex, age, white matter hyperintensity volume, infarction, 
cortico-subcortical MBs, deep white matter MBs, and basal ganglia MBs.
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Table 7.4. Demographic characteristics of subjects with infratentorial microbleeds.
Continuous variables means (SD)
Age, y 78 (3)
Systolic blood pressure, mm Hg 155 (17)
Diastolic blood pressure, mm Hg 84 (7)
Total cholesterol, mmol/L 5.08 (1.0)
LDL cholesterol, mmol/L 3.19 (1.0)
HDL cholesterol, mmol/L 1.23 (0.30)
Triglycerides, mmol/L 1.53 (0.64)
Body Mass Index 26.0 (3.2)
WMH volume, mL 8.4 (8.9)
Categorical variables n (%)
Male gender 15 (60)
Current smoker 3 (12)
History of diabetes 6 (24)
History of hypertension 19 (76)
History of myocardial infarction 5 (20)
History of any vascular disease 13 (52)
Infarcta 14 (56)
  
Abbreviations: HDL = high-density lipoprotein; LDL = low-density lipoprotein; WMH 
= white matter hyperintensity. 
a = no symptoms <6 months before entering the study
Cerebral Microbleeds and Cognitive Functioning 
91 
Discussion
The most important finding of this study is that MBs are associated with loss 
of cognitive functioning when these MBs are located infratentorially. This 
association was corrected for sex, age, WMH volume, infarction, and the 
presence of MBs at other anatomic regions. 
The prevalence of MBs found in our study (24%) is higher than that found in 
the general population and comparable to the prevalence observed in previous 
studies investigating patients with first-ever ischemic stroke using comparable 
imaging protocols.23 However, the prevalence is substantially lower compared to 
the prevalence found in patients with recurrent ischemic stroke (43.6%), first-
ever intracerebral hemorrhage (51.8%), and recurrent intracerebral hemorrhage 
(82.5%), again using similar imaging protocols.23 
Studies on cognitive impairment in patients with MBs are scarce. In a previous 
study in patients with subcortical vascular dementia (SVaD) it was demonstrated 
that the number of MBs is an independent predictor of cognitive functioning in 
multiple domains and dementia severity.157 In that study, 73 patients with SVaD 
had a median of 13 MBs (mean 56.8; range 1 - 163). In addition, a correlation 
between MBs in the frontal lobes and basal ganglia and executive dysfunctioning 
has been found in a small heterogeneous population of clinical stroke patients.147 
The mean MBs count in that study was 6.4 (range 1 - 32) and 68% of the MBs 
were located in the basal ganglia. As these studies were performed in subjects 
with specific cerebrovascular diseases, both with their own distinct prevalence 
and distribution of MBs, the conclusions drawn from these studies cannot be 
extrapolated to the aging population as a whole. However, these studies showed 
that MBs are not to be considered clinically silent, as has been suggested in the 
past, and their results raised the question whether MBs might also contribute 
to cognitive decline in the aging population. One study addressed this question 
and showed that a higher prevalence of microbleeds is found in subjects with a 
MMSE score >1.5 standard deviations below the age-related mean.158 However, 
this study included subjects with a wide age range (30 to more than 70 years) 
and relatively few elderly (29 subjects older than 70 years). Therefore the 
implications for the aging population, the population in which MBs are most 
commonly found, are still unknown. Furthermore these inclusion criteria led 
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to a low prevalence of MBs (6.8%) which might have obscured associations 
between MBs and their functional consequences due to type II errors, especially 
when MBs are subdivided to location. Furthermore, the MMSE was used as the 
only parameter of cognitive functioning although it is known that the MMSE 
has a low sensitivity for the assessment of cognitive function in patients with 
cerebral smallvessel disease.105 
Several mechanisms can be responsible for the observed association between MBs 
and functional changes, even in the absence of concomitant large, symptomatic 
hematomas. MBs are an indicator of a more widespread disease of the arterioles 
that share a disease process affecting the media of the vascular wall such as 
amyloid deposition in cerebral amyloid angiography and granular osmiophilic 
material in cerebral autosomal dominant arteriopathy with subcortical infarcts 
and leukoencephalopathy. Apart from this, there is also evidence that MBs 
themselves give rise to tissue damage. In a histologic study it was observed that 
the hemosiderin depositions that are characteristic for MBs can be surrounded 
by gliosis, infarction, and necrosis.146 Such changes, if positioned at strategic 
locations, could also contribute to cognitive decline. However, this study does 
not elucidate the mechanisms underlying the association between MBs and 
cognitive decline. 
In our study we found an association between infratentorial MBs and lower scores 
on the IADL. The brainstem and cerebellum are extensively involved in motor 
functioning and damage to these structures is likely to interfere with the IADL 
as reflected in the IADL score. It is known that brainstem and cerebellar damage 
can lead to a variety of symptoms and that those symptoms are not limited to 
motor signs but also include higher cortical functions. This could be explained 
by impaired involvement of the cerebellum in timing of processes and temporal 
regulation or the disruption of the excitatory impulses from the cerebellum to 
the cortex involved in cognitive functioning.163 In this study we saw impaired 
cognitive function expressed in lower scores on the PWLT for subjects with 
infratentorial MBs. This is in line with a previous study showing impairment in 
the learning condition of Rey’s word list (from which the picture word learning 
list is derived) in patients with isolated cerebellar infarcts in the posterior inferior 
cerebellar artery territory.164 Regarding isolated brainstem lesions, it is known 
that these lesions can cause deficits in various cognitive domains independent 
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of their size and exact location.165 Furthermore, in previous studies it has been 
shown that infratentorial stroke is associated with impaired higher cortical 
functioning, including delayed memory.166 
The population included in this study is strictly selected for the PROSPER study 
and consists of subjects with or at high risk for developing vascular disease. Our 
post hoc analysis of MBs in this population has a reduced generalizability to the 
general aging population. This constitutes a major limitation of this study. Another 
point that might limit the generalizability of this study investigating cognition 
is that informed consent was required from all included subjects. However, the 
study population does represent a substantial part of the aging subjects given the 
high prevalence of vascular risk factors in the elderly. Furthermore, investigating 
the association between MBs and cognition benefits from population with 
an increased prevalence of MBs, such as our study population, since it allows 
the assessment of the influence of MBs on cognition without the risk of type 
II errors. These type II errors will be encountered in studies investigating the 
healthy population as they have a lower prevalence of MBs. Furthermore, our 
inclusion criteria and large sample size allowed the analysis of MBs located 
in different anatomic regions. A statistical consideration in this study is the 
multiple hypothesis testing (type I error) and positive results might have been 
yielded by chance alone although this is unlikely as all significant differences are 
consistently found for infratentorial MBs only. Therefore, this study should be 
regarded as an exploratory study that needs confirmation in future studies.
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Abstract
In this study we investigated patterns of hypointense basal ganglia on T2*-
weighted magnetic resonance imaging (MRI) in 413 non-demented elderly 
(range: 70–82 years, mean 77 years; male/female: 177/239). In addition, we 
assessed associations between these patterns and age-related changes in the 
brain. Three patterns were noted: hypointensity limited to the globus pallidus 
(group I; n = 30; 7%), hypointensity of both globus pallidus and putamen 
(group II; n = 272; 66%), and hypointensity of globus pallidus, putamen and 
caudate nucleus (group III; n = 111; 27%). Group III demonstrated a higher 
volume of white matter hyperintensities, more atrophy, decreased whole brain 
magnetization transfer ratios and increased T2-values compared to groups I and 
II. No differences were observed between groups I and II. From this study we 
conclude that hypointensity of the caudate nucleus is associated with a higher 
load of age-related cerebral changes. These data suggest that hypointensity of the 
caudate nucleus could be a new biomarker of age-related changes in the brain.
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Introduction
An age-related progressive shortening of T2 relaxation time, resulting in a 
decrease in signal intensity on T2-weighted magnetic resonance imaging 
(MRI) has been found in the basal ganglia in previous studies.167-169 It has been 
demonstrated that the development of hypointense basal ganglia follows a 
specific age-related pattern with the globus pallidus becoming hypointense in 
early adulthood whereas the putamen darkens after the age of approximately 70 
years.168 This pattern of signal changes over time is supposed to be part of the 
cerebral changes that accompany aging.170 However, it has been suggested that 
hypointensity of the caudate nucleus does not belong to this normal spectrum.168 
The age-related decrease in signal intensity of the basal ganglia is attributed to 
increasing iron concentrations.167;170 Iron is the most abundant paramagnetic 
element in the brain and present in two forms: heme iron and non-heme iron. 
Both of these forms enhance proton relaxation and therefore contribute to the 
MRI signal.171;172 Neuropathological studies have shown high concentrations 
of iron in the substantia nigra, red nucleus and dentate nucleus whereas lower 
concentration of iron can be detected in the striatum, thalamus and both cerebral 
grey and white matter.170 Furthermore, Hallgren and Sourander173 showed 
that the accumulation of iron in the brain shows regional differences with the 
globus pallidus being the preferred site. Less iron is accumulated, for example, 
in the caudate nucleus and thalamus. The mechanism responsible for this 
phenomenon of iron accumulation is poorly understood. It has been suggested 
it is based on a decreased efficiency of the usual axonal transport of iron from 
the basal ganglia to its projection areas elsewhere in the brain caused by age-
related loss of neurons.174-177 Excessive and premature deposition of iron in the 
basal ganglia has been reported in neurodegenerative diseases like Alzheimer’s 
disease178, Parkinson’s disease179;180, Huntington’s disease179 and multiple 
sclerosis (MS)181;182. These observations support the theory that hypointensity 
in the brain is, at least partly, based on degenerative processes in the brain. 
At present, it is unknown whether hypointensity in the caudate nucleus belongs 
to the spectrum of normal age-related changes in the brain. Furthermore, it is 
unknown whether hypointensity in the basal ganglia is associated with changes 
elsewhere in the brain. The aims of the present study were (1) to assess the 
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patterns of hypointensity of the basal ganglia in a large sample of non-demented 
elderly individuals, (2) to assess the relationship between these patterns and 
quantitative measures of cerebral changes elsewhere in the brain.
Methods
Patients
Patients were included from the nested MRI substudy of the PROspective 
Study of Pravastatin in the Elderly at Risk (PROSPER).108 Inclusion criteria 
for this study were men or women aged 70 - 82 years; total cholesterol 4.0 - 
9.0 mmol/L; stroke, transient ischemic attack, myocardial infarction, arterial 
surgery, or amputation for vascular disease >6 months before study entry; ≥1 
of the following risk factors for vascular disease: current smoker; hypertension, 
currently receiving drug treatment; known diabetes mellitus or fastening 
blood glucose >7 mmol/L. Exclusion criteria have been described in detail 
elsewhere.108 We chose this population for our study, since it is known that age-
related changes in the brain are correlated with cardiovascular risk factors.183;184 
Hence, the prevalence of age-related changes can be expected to be increased in 
our population, which created an enriched population in terms of such changes. 
MRI data were available for 429 patients. Sixteen patients were excluded due to 
suboptimal image quality caused by movement or artefacts on the T2*-weighted 
scan.
MRI scanning
All imaging was performed on an MR system operating at a field strength of 
1.5 T (Philips Medical Systems, Best, The Netherlands). Dual fast spin echo 
[repetition time (TR) = 3000 msec; echo time (TE) = 27 / 120 msec; flip angle 
= 90°; slice thickness = 3 mm; 48 slices; no interslice gap; field of view (FOV) 
= 220 mm x 220 mm; matrix = 256 x 204], fluid-attenuated inversion recovery 
(FLAIR) [TE = 100 msec; TR = 8000 msec; flip angle = 90°; slice thickness 
= 3 mm; 48 slices; no interslice gap; FOV = 220mm x 176 mm; matrix = 256 
x 153] and T2*-weighted images [multislice gradient echo sequence; TE = 48 
msec; TR = 2593 sec; flip angle = 60°; slice thickness = 6 mm; 22 slices; interslice 
gap = 6 mm; whole brain coverage; FOV = 220mm x 198 mm; matrix = 256 
x 176] were obtained from all subjects. In addition to these conventional MR 
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sequences, magnetization transfer imaging (MTI) of the brain was performed 
using a three-dimensional (3D) gradient echo pulse sequence [28 axial slices, 
slice thickness = 5 mm; no interslice gap; TR / TE 106 / 6 msec; flip angle = 12°; 
FOV = 220 mm x 220 mm; matrix = 256 x 256; a sinc-shaped saturation pulse 
1100 hertz below frequency of water was added].50 These scan parameters were 
chosen to minimize T1 and T2 weighting, resulting in a proton-density contrast 
in the absence of MT saturation pulses. Two consecutive sets of images were 
acquired; the first was performed in combination with the MT saturation pulse, 
and the second without.
MRI analysis: basal ganglia hypointensity
Our rating scale was developed to provide a qualitative analysis of the basal 
ganglia intensity on T2*-weighted images. The globus pallidus was taken 
as reference structure as it is known to have a high iron concentration170 that 
reaches a plateau around the age of 30, and therefore it was expected to have 
a low signal intensity in all participants in this study.171;173 Hypointensity of 
this structure was confirmed by comparing the intensity of the globus pallidus 
with that of the center semiovale, a region that is expected to show no low 
signal intensity at any time. The advantage of using this region as an internal 
reference is that it reduces the effect of different image qualities and window 
levelling between subjects. The caudate nucleus, putamen and thalamus (Figure 
8.1.) were then rated as being hyperintense or having a signal intensity that was 
isointense compared to the globus pallidus. With the globus pallidus being the 
gold standard for hypointensity, structures were considered hypointense if they 
were isointense compared to the globus pallidus. The basal ganglia were scored 
on all slices covering the basal ganglia. These ratings were performed by two 
experienced readers in consensus (AvE, MvB). Fifty images were rated twice by 
both individual raters, with an interval of 1–2 weeks, to determine the inter- and 
intra-observer agreement.
MRI analysis: white matter hyperintensities, atrophy and quantitative MR 
parameters
Segmentation of white matter hyperintensities (WMH), intracranial volume, 
and brain parenchyma volume was performed automatically using Software for 
Neuro-Image Processing in Experimental Research (SNIPER)65, an in-house 
developed program for image processing. This segmentation was done on the 
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T2-weighted and FLAIR images. Hyperintensities connected in or through plane 
to the lateral ventricles were labelled as periventricular WMHs (PVWMH). 
Hyperintensities not connected to the lateral ventricles were labeled as deep 
WMHs (DWMH).148 The volume of PVWMH and DWMH was calculated 
automatically.65 All measurements were performed blinded to subject identity, 
age and sex. A measure reflecting atrophy was calculated using the equation: 
atrophy (%) = ((intracranial volume − parenchymalvolume) / intracranial 
volume) × 100%.
For the assessment of quantitative MR parameters based on T2 relaxation times 
and magnetization transfer ratio (MTR), the proton density (PD) image was 
used to create an intracranial mask. Subsequently, the PD and T2 images were 
combined to generate segmentations of GM and WM. The segmented WMH 
were extracted from the WM segmentation to yield normal appearing brain 
Figure 8.1. An example of the scoring method used in this study. The globus pallidus 
(GP) intensity was used as a reference for regions containing a high iron concentration. 
In this example the putamen (PT) was rated isointense compared to the globus pallidus, 
whereas the caudate nucleus (CN) and thalamus (TH) were rated hyperintense.
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tissue. Third, a custom template was applied to exclude the cerebellum, brainstem 
and basal ganglia from analysis. Finally, these masks were co-registered to the 
MT images. The MTR for each voxel within the GM and WM, respectively 
was calculated automatically using the equation MTR = ((M0 − Ms) / M0)) 
x 100%, in which Ms represents the signal intensity of voxels with saturation 
and M0 represents the intensity of voxels without saturation.50 In the resulting 
MTR map, voxel values represent the percentage of signal loss caused by transfer 
of magnetization of the saturated immobile macromolecular-bound to the free 
water pool of protons. The frequency distributions of  MTR values were displayed 
as MTR histograms of the cortical GM and NAWM, respectively.68 From each 
histogram, the mean MTR and the peak height – two measures reflecting 
structural brain damage – were derived. The peak height was normalized for the 
size of the segmented compartment by dividing the number of voxels on the 
peak by the total number of segmented voxels. The normalized peak height thus 
obtained is a measure reflecting the amount of remaining normal brain tissue, 
independent of brain size and atrophy.46 The dual fast spin echo images were 
used for the estimation of T2-values. 
Statistical analysis
SPSS for Windows (release 10.0; SPSS, Chicago, IL) was used for data analysis. 
Categorical variables were analyzed using a Chi-Square test and Kruskal–
Wallis tests when appropriate. Kruskal–Wallis tests were used due to the large 
differences in group sizes. Inter- and intra-observer reliability was determined 
on re-readings of 30 patients using Cohen’s κ coefficient. The level of statistical 
significance was set at p < 0.05.
Results
In this study the Cohen’s κ for the putamen intensity score was 0.889, whereas 
the κ for the caudate nucleus intensity score was 0.902 for the inter-observer 
agreement. Intra-observer agreement was found to be 1, for both readers and for 
both putamen and caudate nucleus score. The globus pallidus was hypointense 
in all patients. In addition, the thalamus was never found to be isointense 
compared to the globus pallidus. This was the case in both the consensus reading 
and during the readings for assessing the reproducibility of our assessment. 
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Table 8.1. Age and sex distribution.
Group
I
(n=30)
II
(n=272)
III
(n=111) p
Age (yrs)a 78 (74 - 80) 77 (74 - 79) 78 (75 – 80) 0.18
Sex (m/f)b 16/14 120/152 41/70 0.11
Group I: only globus pallidus hypointensity 
Group II: hypointensity of both globus pallidus and putamen 
Group III: hypointensity of globus pallidus, putamen and caudate nucleus 
a Jonckheere-Terpstra [median (p25 – p75)]
b Chi-square
Table 8.2. White matter hyperintensities and atrophy.
Group
I 
(n=30)
II
(n=272)
III
(n=111)
% Atrophy (SE) 25.9 (0.6) 27.0 (0.2) 28.0*† (0.3)
Volume of WMH
Total [ml, (SE)] 5.4 (1.5) 6.1 (0.5) 9.4*† (1.4)
Periventricular [ml, (SE)] 4.2 (1.3) 4.7 (0.4) 7.4*† (1.2)
Deep [ml, (SE)] 1.2 (0.4) 1.3 (0.1) 2.1*† (0.3)
SE = Standard Error
Atrophy was calculated using the formula: atrophy (%) = ((intracranial volume – 
parenchymal volume) / intracranial volume) x 100 %. 
WMH = White matter hyperintensity
Group I: only globus pallidus hypointensity 
Group II: hypointensity of both globus pallidus and putamen 
Group III: hypointensity of globus pallidus, putamen and caudate nucleus 
* Differs from group I (p < 0.05)
† Differs from group II (p < 0.05)
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In our study we found three distinct patterns of basal ganglia hypointensity: 
only globus pallidus hypointensity (group I; n = 30; 7%), hypointensity of both 
globus pallidus and putamen (group II; n = 272; 66%), and hypointensity of 
globus pallidus, putamen and caudate nucleus (group III; n = 111; 27%). Figure 
8.2 shows three examples for each of the groups. 
Between these three groups, we found no difference in age or sex (Table 8.1). 
Table 8.2 shows that subjects with a hypointense caudate nucleus (group III) 
have a larger total WMH volume then subjects in groups I and group II. When 
WMH volume was subdivided, we found that the volumes of both periventricular 
and deep WMH lesion were larger in group III compared to groups I and II. In 
addition to this higher WMH lesion load, subjects in group III were found to 
have more atrophy. No differences were found between group I and group II.
Table 3 shows the quantitative MR parameters of the cortical gray matter and 
NAWM of the three subgroups. Subjects in group III demonstrated a decreased 
mean MTR, a decreased MTR peak height and increased mean T2-values 
compared to group I and group II. Quantitative MR parameters did not show 
any differences between group I and group II.
Discussion
The most important findings of this study are twofold. (1) This is the first study 
to show that low signal intensity of the caudate nucleus is a frequent finding in 
non-demented elderly subjects. (2) Low signal intensity of the caudate nucleus 
on T2*-weighted MR is associated with more atrophy and a higher load of 
WMH and a higher load of invisible changes in both cortical GM and NAWM. 
In contrast, hypointensity limited to the globus pallidus and putamen is not 
associated with any of these parameters of neurodegeneration. 
In this study, in which the mean age of our population was 77 years, the globus 
pallidus was found to be hypointense on T2*-weighted images in all subjects 
investigated (413 / 413; 100%). This high prevalence of globus pallidus 
hypointensity is expected, since in previous studies it has been demonstrated that 
hypointensity of this structure occurs as early in life as in the second decade.168;185 
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Figure 8.2. Examples of the different patient groups found in this study. Group I: only 
globus pallidus hypointensity, group II: hypointensity of both globus pallidus and 
putamen, and group III: hypointensity of globus pallidus, putamen and caudate nucleus.
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Table 8.3. Quantitative MR measures.
Group
I
(n=30)
II
(n=272)
III
(n=111)
Mean MTR (SE) WM 35.9 (0.2) 35.5 (0.08) 35.1 (0.1)*†
GM 30.8 (0.4) 30.5 (0.1) 30.1 (0.2)*†
NPH MTR (SE) WM 122.3 (1.0) 120.8 (0.6) 119.0 (0.8)*†
GM 72.6 (2.0) 70.0 (0.6) 68.1 (1.0)*†
Mean T2 (SE) WM 90.0 (0.6) 92.1 (0.3) 92.8 (0.5)*†
GM 112.0 (1.2) 114.7 (1.1) 115.8 (1.8)*†
SE = Standard Error 
MTR = Magnetization transfer ratio
NPH = Normalized peak height
WM = White matter
GM = gray matter
Group I: only globus pallidus hypointensity 
Group II: hypointensity of both globus pallidus and putamen 
Group III: hypointensity of globus pallidus, putamen and caudate nucleus
* Differs from group I (p < 0.05)
† Differs from group II (p < 0.05) 
Furthermore, in our study almost all subjects included (93%; 383 / 413; group 
II and III) demonstrated putamen hypointensity in addition to globus pallidus 
hypointensity. Again this is expected, since it has been documented that the 
putamen starts being hypointense in the seventh decade168, and starts to have an 
equally low signal intensity as the globus pallidus in the eight decade of life.167;170
Contrary to hypointensity of the globus pallidus and putamen Milton et al. 
suggested that hypointensity of the caudate nucleus is not part of the spectrum 
of normal aging.168 Whatever normal aging may exactly be (this term is hard 
to define), our study clearly demonstrates that this radiological feature can 
be observed in a non-demented elderly population. However, the findings in 
this study were based on T2*-weighted images whereas Milton et al. used T2-
weighted images. These differences in contrast might have lead to somewhat 
different conclusions. Furthermore, it should be borne in mind that our study 
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population was not representative for the general aging population as a whole. 
The high prevalence of hypointense caudate nucleus (27%) observed in our 
population, may not reflect the prevalence in the general population, and could 
be based on the presence of vascular disease or risk factors for developing this 
condition in our study group. On the other hand, vascular disease and risk 
factors have a high prevalence in elderly populations of western societies, and 
therefore hypointense caudate nucleus is expected to be a frequent finding in 
such populations. 
The age-related decrease in signal intensity of the basal ganglia has been 
attributed to the accumulation of ferritin, a storage form of nonheme iron.167 
Iron is important for normal functioning of the neurons as it is an essential 
component of cytochromes a, b, and c, oxidase, ATP production synthesis186, 
and a required co-factor for monoamine synthetic187 and degradative enzymes 
tyrosine hydroxylase and tryptophan hydroxylase188. Furthermore, iron is 
essential for biosynthesis of lipids, cholesterol, and may have a role in the GABA-
ergic system189 and neurotransmitter metabolism190;191. It has been suggested that 
transferrin-bound iron is taken up from the blood by capillary endothelial cells 
in the basal ganglia and thalamus and transported from there to other sites of 
the brain by means of axonal transport.175;176 Age-related neuronal death and 
axonal damage may result in a decrease of this axonal transport and that with a 
continuing uptake this could lead to the observed age-related accumulation of 
iron in the basal ganglia. 
However, it remains unclear whether iron deposition is the consequence of a 
disease process or the primary cause. It can be hypothesized that disturbances in 
the iron metabolism results in increased brain iron levels which in turn lead to a 
deleterious process of oxidative stress and neurodegeneration.192 Furthermore, it 
should be kept in mind that although the known high iron content of the caudate 
nucleus strongly suggests that the observed caudate nuclei hypointensity reflects 
changes in iron concentration, form, and/or distribution pattern but other 
causes such as senescent calcification cannot be excluded. 
In this study, we found no differences in cerebral lesion load between individuals 
with only hypointense globus pallidus and those with hypointense globus 
pallidus and putamen, suggesting that variation in iron accumulation in the 
Caudate Nucleus Hypointensity and Neurodegeneration on MRI
107 
putamen is not related to the amount of damage elsewhere in the brain. However, 
individuals with hypointense caudate nuclei had significantly more changes 
elsewhere in the brain than those without. These changes comprised WMH, 
atrophy, and changes in the normal appearing white and gray matter. Age-related 
shrinkage of the caudate nucleus has been reported in previous studies.193 Our 
findings are in line with the findings of Bartzokis et al. who showed that age-
related field-dependent R2 increase of the caudate nucleus cannot be accounted 
for solely by this volume reduction of the structure itself.194 
WMH are commonly seen in the WM of the elderly population and their 
prevalence rises with increasing age.195 The histopathological correlates of 
these lesions are diverse and include enlargement of the perivascular spaces, 
axonal loss, gliosis, and demyelination.196 Another hallmark of the aging brain is 
atrophy, which is caused by cell loss and neuronal shrinkage.197 Quantitative MR 
techniques, such as MTI and T2 relaxation time measurements, have proven 
to be able to detect and quantify changes in brain tissue that appears normal 
on conventional MRI sequences. Using these techniques microstructural 
changes have been detected in the GM and NAWM in various diseases, such 
as Alzheimer’s disease44;198 and multiple sclerosis199;200. Changes have also been 
detected in normal appearing tissue in the aging brain.201 Histopathologically 
changes in the NAWM in the elderly correspond with lower intensity of 
myelin staining and with an accentuation of the distance between fibres.202 
The relationship between hypointensity of the caudate nucleus and this broad 
spectrum of markers of neurodegeneration that we observed in this study is in 
line with previous studies showing that basal ganglia hypointensity can be found 
in a variety of neurodegenerative diseases such as stroke, Alzheimer’s disease 
and multiple sclerosis.177;178;181 Whether this relationship is causal (and whether 
iron accumulation in the caudate nuclei are the cause or the consequence of the 
damage elsewhere in the brain) or whether these phenomena have no causal 
relationship but are rather caused by a common denominator cannot be derived 
from this study. This issue should be addressed in future studies. Furthermore, 
these studies should focus on identifying risk factors for this phenomenon 
and investigate whether hypointensity of the caudate nucleus is independently 
associated with cognition. 
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The visual rating applied in this study could be considered a limitation. 
However, in this study we experienced that the regions investigated did not 
show intermediate signal intensities but a rather binary distribution. That is, the 
signal intensity was never in between that of the center semiovale and the globus 
pallidus, but rather one of these extremes. Therefore, we considered a visual 
rating scale appropriate for the assessment of basal ganglia hypointensity. This 
is also reflected in a high inter- and intra-bserver reliability. Another potential 
limitation of this study is that the analysis of signal intensity was done one type 
of MRI image (T2*-weighted). The inclusion of other MRI sequences would 
have provided information pertaining to the underlying source of the found 
hypointensity. On the other hand, contrary to MRI sequences more dedicated 
to the quantification or iron concentrations, the single use of a T2*-weighted 
sequence combined with a straightforward and reliable visual rating scale 
allowed us to include a large number of subjects. 
In conclusion, hypointense caudate nuclei can be observed in non-demented 
elderly on T2*-weighted images at 1.5 T. This phenomenon is associated with a 
variety of age-related changes in the brain, which suggests that this radiological 
phenomenon might serve as a biomarker for generalized age-related brain 
damage.
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Abstract
Decreased signal intensity of the basal ganglia on T2-weighted magnetic 
resonance imaging (MRI) is frequently observed in elderly individuals and 
in patients with neurodegenerative diseases. The causes and consequences of 
this phenomenon are poorly understood. The aims of this study were to assess 
whether signal loss in the basal ganglia is associated with risk factors and to 
assess whether the degree of signal loss is associated with changes in cognitive 
functioning in the elderly. Our study population consisted of 549 community-
dwelling elderly subjects, who participated in a study comprising an MRI 
examination of the brain, a comprehensive neuropsychological test battery, 
and cardiovascular risk profiling. In this population, the degree of signal loss in 
the basal ganglia was captured using an automated image processing method. 
Age (β = 0.17; p = 0.03), male gender (β = 0.14; p<0.01), triglycerides (β = 
0.10; p = 0.03) and current smoking (β = 0.11; p = 0.02) were associated with a 
higher degree of signal loss in the basal ganglia. On the other hand, a history of 
hypertension was associated with a lower degree of signal loss in the basal ganglia 
(β = -0.11; p = 0.01). After correction for age, sex, white matter hyperintensity 
(WMH) volume, atrophy and infarcts, basal ganglia signal loss was associated 
with both the immediate (β = -0.11; p < 0.01) and delayed component (β = 
-0.12; p < 0.01) of the Picture Word Learning Test. We conclude that signal loss 
of the basal ganglia on T2-weighted MRI in elderly individuals is associated with 
cardiovascular risk factors and loss of memory functions.
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Introduction
The signal intensity of the basal ganglia on MRI becomes gradually lower at 
old age due to T2-relaxation time shortening.167 This phenomenon is based on 
accumulation of iron, mostly in the form of non-heme iron. In the brain, iron 
homeostasis is essential for proper function and plays a pivotal role in a number 
of biochemical processes.203 There is increasing evidence that a number of 
neurodegenerative disorders are associated with increased iron accumulation 
in the brain.204 Also, the degree of iron accumulation in the brain varies widely 
between aging individuals. However, the causes and potential consequences 
of this individual variation in basal ganglia signal loss in the elderly remains 
unknown.
 
Two phases in our life are characterized by relatively rapid changes in iron 
accumulation in the brain that are apparent on MR images. During the first two 
decades of life iron accumulates in the globus pallidus, red nucleus, substantia 
nigra and dentate nucleus. After the second decade the iron concentration 
increases more gradually in the putamen and caudate nucleus, leading to the 
homogeneous pattern of low T2 signal intensity of the those structures as seen in 
the middle aged.173;205 In the caudate nucleus, the globus pallidus and the putamen, 
iron accumulation further increases in old age178;206, resulting in a second period 
of increasing basal ganglia signal loss. In addition, signal loss of these structures 
does not only increase but also becomes more heterogeneous after the age of 
60.207 In a previous study we have shown that this variation in patterns of signal 
loss in the basal ganglia in the elderly population is associated with various MRI 
markers of neurodegeneration.149 Especially a strong association with WMH 
volume was observed. With the knowledge that cardiovascular risk factors for 
white matter hyperintensities have been firmly established, we hypothesized that 
specific cardiovascular risk factors can also been defined for signal loss in the 
basal ganglia.
The goal of this study is twofold: first, to define risk factors for increased signal 
loss in the basal ganglia on T2-weighted MR images in the elderly; second, to 
investigate whether the volume of basal ganglia affected by hypointensity is 
associated with cognitive performance in the elderly.
Chapter 9
112
Materials and Methods
Patients
Patients were included from the nested MRI substudy of the PROspective Study 
of Pravastatin in the Elderly at Risk (PROSPER). Inclusion criteria for this study 
were: men or women aged 70-82 years; total cholesterol 4.0-9.0 mmol/L; stroke, 
transient ischemic attack, myocardial infarction, arterial surgery, or amputation 
for vascular disease >6 months before study entry; ≥1 of the following risk 
factors for vascular disease: current smoker; hypertension, currently receiving 
drug treatment; known diabetes mellitus or fastening blood glucose >7 
mmol/L. Exclusion criteria have been described in detail elsewhere.108 This 
study population was enriched for investigating potential cardiovascular risk 
factors for signal loss in the basal ganglia as all subjects had a history of, or were 
at increased risk for, vascular disease. All cardiovascular risk factors investigated 
in this study are displayed in Table 9.1. MRI data and measures of cognitive 
functioning were available for 549 subjects. 
Table 9.1. Demographic characteristics.
Continuous variates mean (SD) median 25 perc. 75 perc.
Age, years  74.5 (3.2) 74.0 72.0 77.0
Systolic blood pressure, mmHg 157.9 (21.7) 158.0 142.0 172.0
Diastolic blood pressure, mmHg 85.9 (11.0) 85.0 80.0 92.0
Total cholesterol, mmol/L  5.8 (0.8) 5.7 5.2 6.3
LDL cholesterol mmol/L 3.9 (0.7) 3.9 3.4 4.3
HDL cholesterol, mmol/L 1.2 (0.3) 1.2 1.0 1.4
Triglycerides, mmol/L 1.5 (0.7) 1.3 1.1 1.8
Categorical variates n (%)
Male gender 297 (55.9)
Current smoker 115 (20.8)
History of diabetes 90 (14.4)
History of hypertension 338 (63.7)
History of myocardial infarction 65 (10.4)
History of any vascular disease 227 (36.3)
Basal Ganglia T2 Hypo-intensity: Risk factors and Clinical Consequences
113 
MRI scanning
All imaging was performed on an MR system operating at a field strength of 1.5 
Tesla (Philips Medical Systems, Best, The Netherlands). Dual fast spin echo 
[repetition time (TR) = 3000 msec; echo time (TE) = 27/120 msec; flip angle 
= 90°; slice thickness = 3 mm; 48 slices; no interslice gap; field of view (FOV) = 
220 x 220 mm; matrix = 256 x 204], fluid-attenuated inversion recovery (FLAIR) 
[TE = 100 msec; TR = 8000 msec; flip angle = 90°; slice thickness = 3 mm; 48 
slices; no interslice gap; FOV = 220 x 176 mm; matrix = 256 x 153] and T2*-
weighted images [multislice gradient echo sequence; TE = 48 msec; TR = 2593 
msec; flip angle = 60°; slice thickness = 6 mm; 22 slices; interslice gap= 6 mm; 
whole brain coverage; FOV = 220 x 198 mm; matrix = 256 x 176] were obtained 
from all subjects.
MRI analysis: WMH, atrophy and infarcts
Segmentation of WMH volume, intracranial volume, and brain parenchyma 
volume was performed automatically using Software for Neuro-Image Processing 
in Experimental Research (SNIPER)65, an in-house developed program for 
image processing. This segmentation was performed on T2-weighted and 
fluid-attenuated inversion recovery (FLAIR) images. All measurements were 
performed blinded to subject identity, age and sex. A measure reflecting atrophy 
was calculated using the equation: atrophy (%) = ((intracranial volume – 
parenchymal volume) / intracranial volume) x 100 %.149;208 Infarcts were defined 
as brain parenchyma defects with a diameter equal to or larger than 4 mm and 
a signal intensity isointense to that of cerebrospinal fluid (CSF) on all pulse 
sequences. Furthermore, these lesions showed a surrounding rim of high signal 
intensity on FLAIR and followed a vascular distribution. 
MRI analysis: basal ganglia hypo-intensity volume analysis
Our basal ganglia hypo-intensity volume (BGHV) analysis consists of three 
elements which are described next. 
I: Brain Structure Selection
Selection of the basal ganglia structures was realized by finding the volume-of-
interest (VOI) followed by the region-of-interest (ROI). To implement VOI 
computation, skull stripping, vertical alignment of all brain volumes and slice 
selection based on lateral ventricle shape information was performed (figure 
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9.1a). The slice selection process is based on selecting the VOI slices that contain 
the cornu anterior of the lateral ventricles by using a binary template. Following 
this we determined the ROI by computing a bounding box of VOI slices and 
divide it into 9 by 8 blocks, similarly to the Talairach-Tournoux brain atlas grid 
blocks. The ROI is given by the collection of blocks containing the basal ganglia 
structures (Figure 9.1b).
II: Image Normalization
After gray matter, white matter and CSF segmentation, the difference in image 
brightness between pixels in the ROI (basal ganglia) and the average image 
brightness in the cortex divided by this average was computed. The cortex used 
for this image normalization is shown by the green rectangles in figure 9.1b. 
III: T2-weighted Hypo-intensity Detection
The segmentation of hypo-intense pixels in the ROI is based on a threshold. For 
the computation of this threshold, the threshold was independently determined 
in a training set of 20 brain T2-weighted by two specialists. The final threshold 
was determined in a consensus reading (Figure 9.1c). The definitive result of 
the segmentation process is shown in figure 9.1d. The BGHV was computed by 
multiplying the number of segmented voxels by the voxel size.
Measures of cognitive functioning
Cognitive functioning was assessed using a battery of neuropsychological tests. 
The battery was designed to assess global cognitive functioning with a specific 
focus on memory and executive functioning. Global cognitive functioning 
was tested using the Mini Mental State Examination (MMSE).47 Memory 
Figure 9.1. The skull stripped T2-weighted image (a). The ROI shown as red blocks and 
the cortex used for image normalization as green blocks. (b). The manually annotated 
slice, were white pixels are tagged as hypointense, and black pixels are tagged as the 
remaining non-hypointense (c). Final result of the segmentation process (d).
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functioning was estimated with the Picture Word Learning Test (PWLT).159 
Tests of executive functioning and attention included the Letter Digit Coding 
Test (LDCT) and the abbreviated Stroop Color Word Test.160 The PWLT was 
derived from the Fifteen Words Test161, originally described by Rey. In this test, 15 
pictures are presented sequentially to the subject, who is asked to recall as many 
objects as possible. This process is repeated three times and, after 20 minutes, 
delayed recall is tested. The LDCT we used is a modification of the procedurally 
identical Symbol Digits Modalities Test, used to measure the speed of processing 
general information.159 The Stroop test has often been used to test selective 
attention and speed of processing; subjects are asked to successively read sheets 
with (a) colour names, (b) coloured patches and (c) colour names printed in 
incongruously coloured ink. In the latter, subjects have to name the colour of the 
word, not the word itself. In our analyses we used the average number of items 
reported correctly in the three immediate recall conditions (immediate PWLT 
(PWLTimm)), the number of items correctly generated in the delayed recall 
condition (delayed PWLT (PWLTdel)), the number of correct digits for the 
LDCT, and time to complete the colour interference section of the Stroop test. 
The Barthel index was used as a measure of activities of daily living (ADL).162 
The Barthel index gives a score out of 20, principally concerned with physical 
aspects of disability. The IADL measures the instrumental activities of daily 
living. These activities are related to independent living and include preparing 
meals, managing money, shopping for groceries or personal items, performing 
light or heavy housework and using a telephone. The maximum IADL score is 
27. 
Statistical analysis
SPSS for Windows (release 17.0; SPSS, Chicago, IL) was used for data analysis. 
Associations between BGHV and risk factors were calculated using a linear 
regression model adjusted for age and sex. For assessment of associations 
between BGHV and cognitive parameters the same statistical model with the 
additional adjustment WMH volume, atrophy and infarcts was used. The level of 
statistical significance was set at p < 0.05.
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Table 9.2. MRI characteristics.
Continuous variates mean (SD) median 25 perc. 75 perc.
Basal ganglia hypo-intensity volume 
(BGHV), mL 1.050 (815) 0.858 0.412 1.467
White matter lesion volume, mL 5.3 (9.7) 1.7 0.5 5.9
Brain parenchyma volume, mL 1071 (100) 1066 966 1137
Cerebral atrophy, %* 26.2 (3.1) 26.0 24.3 27.9
Categorical variates n (%)
Classical infarcts 58 (10.5)
Silent infarcts 48 (8.7)
Lacunar infarcts 110 (20.1)
*atrophy (%) = ((intracranial volume – parenchymal volume) / intracranial volume) x 
100 %. 
Table 9.3. Cognitive characteristics.
mean (SD) median 25 perc. 75 perc.
Global Cognitive Functioning
MMSE (points) 28.2 (1.5) 28 27 29
Memory
PWLT immediate (words)
PWLT delayed (words)
10.1 (1.8)
11.2 (2.6)
10.3
12.0
9.0
9.0
11.3
13.0
Executive Functioning
LDCT (digits/min)
Stroop (seconds)
27.7 (7.1)
55.1 (17.8)
28.0
51.2
23.0
43.6
33.0
61.4
Activities of Daily Living
Barthel Index (points)
IADL (points)
19.8 (0.6)
13.6 (0.8)
20.0
14.0
20.0
13.0
20.0
14.0
MMSE = Mini Mental State Examination
PWLT = Picture Word Learning Test
LDCT = Letter Digit Coding Test
IADL = Instrumental Activities of Daily Living
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Results
The demographic and MRI characteristics of the study population are shown in 
respectively table 9.1 and table 9.2. Table 9.3 describes the cognitive performance 
of the subjects included in this study.
We found that BGHV was associated with age (β = 0.17; p = 0.03, corrected 
for sex), sex (β = 0.14; p < 0.01, corrected for age), “triglycerides” (β = 0.10; 
p = 0.03, corrected for sex and age) and “current smoker” (β = 0.11; p = 0.02, 
corrected for sex and age). A history of hypertension (β = -0.11; p = 0.01) was 
associated with a lower BGHV after correction for age and sex. These results are 
displayed in table 9.4.
Table 9.4. Associations between BGHV and cardiovascular risk factors.
Continuous variates B (SE) Beta p
Age, years 440 (199) 0.17  0.03
Systolic blood pressure, mmHg -2530 (1375) -0.09  0.07
Diastolic blood pressure, mmHg -1041 (679) -0.07  0.13
Total cholesterol, mmol/L 19 (51) 0.02  0.70
LDL cholesterol mmol/L -9 (45) -0.01  0.84
HDL cholesterol, mmol/L 0 (19) 0.00  0.98
Triglycerides, mmol/L 91 (41) 0.10  0.03
Categorical variates
Male gender 94 (31) 0.14 <0.01
Current smoker 58 (25) 0.11  0.02
History of diabetes 40 (24) 0.08  0.10
History of hypertension 73 (29) -0.11  0.01
History of myocardial infarction 15 (21) 0.03  0.46
History of any vascular disease 6 (31) 0.01  0.83
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After correction for age, sex and MR parameters with a known association with 
cognitive functioning (WMH, atrophy and infarcts) “PWLTimm” (β = -0.11; 
p<0.01) and “PWLTdel” (β = -0.12; p < 0.01) were the parameters of cognitive 
functioning associated with higher BGHV. No associations were found between 
BGHV and “MMSE”, “LDCT”, “Stroop test”, “Barthel-index” and “IADL” (table 
9.5).
Table 9.5. Associations between hypointensity BGHV and cognitive functioning.
B (SE) Beta p
Global Cognitive Functioning
MMSE (points) -21.8 (23.4) -0.41  0.35
Memory
PWLT immediate (words)
PWLT delayed (words)
-54.8 (20.0)
-36.8 (13.3)
-0.11
-0.12
<0.01
<0.01
Executive Functioning
LDCT (digits/min)
Stroop (seconds)
-3.85 (5.12)
 0.41 (2.02)
-0.03
 0.01
 0.45
 0.84
Activities of Daily Living
Barthel Index (points)
IADL (points)
-77.5 (58.3)
-62.1 (44.3)
-0.58
-0.06
 0.18
 0.16
MMSE = Mini Mental State Examination
PWLT = Picture Word Learning Test
LDCT = Letter Digit Coding Test
IADL = Instrumental Activities of Daily Living
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Discussion
The main finding of this study is that increased volumes of hypointensity in the 
basal ganglia of an elderly population are associated with a) higher age, male sex, 
higher triglycerides, smoking, and b) with decreased memory functioning. 
To our knowledge, this is the first study to investigate the risk factors for signal 
loss in the basal ganglia in the elderly. The risk factors found in this study, namely 
triglycerides serum concentration, male gender, and smoking, are well-established 
risk factors for cerebrovascular disease. The finding of BGHV being associated 
with increasing age is in line with previous studies showing an increased T2-
shortening in basal ganglia with increasing age.168;178;185;209 The finding of a higher 
BGHV in men is supported by with a recent in-vivo MRI study by Bartzokis et 
al. who demonstrated higher iron levels, reflecting ferittin, in the caudate nucleus 
and thalamus of men compared to women using field dependent relaxation rate 
increase (FDRI) technique.206 This observation was attributed to the fact that 
women have lower peripheral iron levels, as expressed in lower serum ferittin, 
compared to men. The counterintuitive finding of a history of hypertension 
being associated with a lower BGHV could be explained by the fact that all 
subjects in our study were adequately treated for this condition. This resulted in 
well-controlled blood-pressure long before MR imaging was performed, which 
may have led to the lower BGHV found in these subjects. 
Iron accumulation is commonly regarded as the cause for progressive T2-
relaxation time shortening, and the resulting low signal intensity of the basal 
ganglia found in the aging brain due to dephasing of the MR signal.210 Iron is 
a paramagnetic element which is abundantly present in the deep gray matter 
structures of the brain, mainly in the form of ferritin, a storage form of non-
heme iron.171 In ferritin, iron reduces T2 relaxation but has almost no effect on 
T1 relaxation times due to its protein shell.211 A large number of studies have 
found strong correlations between tissue relaxation times on the one hand 
and iron concentration as mentioned in literature or directly measured tissue 
concentrations on the other.171 Iron can exert neurotoxic effects by transferring 
electrons to molecular oxygen, resulting in the formation of highly reactive free 
radicals.212 These free radicals initiate lipid peroxidation which in turn leads to 
membrane damage and neuronal death.212 Whether such mechanisms are active 
in age-related accumulation of iron in the brain remains to be determined.
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With respect to the causes of age-related iron accumulation in the brain, various 
mechanisms have been suggested in the literature. Increased delivery of iron to 
the brain due to blood-brain barrier dysfunction, decreased clearance of iron co-
enzymes, a dysregulation of brain iron transport proteins, and a reduced cellular 
energy production due to hypometabolism, have all been suggested to contribute 
to increased iron deposition.167;203 On the other hand, increased iron content 
could also be the result of a neurodegenerative process elsewhere in brain. Iron 
bound to transferrin is extracted from the circulation by capillary endothelial 
cells in the basal ganglia. Subsequently, iron is transported from the basal 
ganglia to projection sites elsewhere in the brain by means of retrograde axonal 
transport.175;176 Disruption of this axonal transport mechanism due to neuronal 
damage elsewhere in the brain could, in combination with a continuing uptake, 
result in increasing iron accumulation in the basal ganglia. This mechanism might 
be responsible for the observed T2 shortening found in the basal ganglia after 
(lacunar) infarction and diffuse ischemic injury174;177;213 but might also explain 
the darkening of the basal ganglia on T2-weighted MRI images found in various 
neurodegenerative diseases. 
Especially in MS, T2 signal intensity changes of the basal ganglia have been well 
studied. In these studies it was found that hypo-intensity of the basal ganglia 
correlated with MR markers of disease like atrophy and lesion load and lesion 
progression181;214 but also with clinical outcome182 and cognition215. Furthermore, 
T2 signal intensity in the basal ganglia changes is found to accompany various 
neurodegenerative disease such as Alzheimer’s disease (AD)178, Parkinson’s 
disease170;179 and Huntington’s disease179. In a previous study we have shown that 
in elderly individuals hypointensity of the caudate nucleus on susceptibility-
weighted MR is associated with more atrophy, a higher load of WMH, decreased 
whole brain magnetization transfer ratios and increased T2-values.149
Although no conclusion can be drawn regarding the exact pathophysiological 
mechanism underlying the basal ganglia hypo-intensity observed in our study, our 
finding of an association between BGHV and decreased cognitive functioning, 
independent of WMH volume and infarcts, suggests that increased BGHV 
has functional consequences independent of neurodegeneration elsewhere 
in the brain. The pivotal role of the basal ganglia in the control movement is 
generally accepted. However, evidence is accumulating that these structures are 
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also involved in other higher cognitive functions.216 Extensive communication 
between the basal ganglia and the cortex exists and disruption of these cortical-
basal ganglia circuits might result in impaired learning and memory.217 
A major strength of this study was the availability of a fully automated and 
quantitative method for the segmentation of basal ganglia hypo-intensity, which 
allowed us to assess BGHV without manual interferences. Therefore, our study 
did not suffer from low inter- and intra-rater reliabilities that can be associated 
with manual delineation of regions of interests. A potential limitation of this 
study is that the analysis of signal intensity was performed on one MRI sequence 
(T2-weighted). The use of different echo-times could have provided information 
regarding the underlying source of the found hypo-intensity.
From this study we conclude that hypo-intensity of the basal ganglia on T2-
weighted MR is not only a radiological finding accompanying cerebral aging, but 
an independent marker of cognitive decline associated with a number of known 
risk factors for cardiovascular disease.
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Summary and Conclusions
The general objective of this thesis was to investigate new (quantitative) 
MR techniques and MR markers in the light of both AD and cerebral aging. 
The quantitative MR techniques that we used were MTI, tCBF and WSS 
measurements. The new markers we studied were cerebral microbleeds and iron 
accumulation in the basal ganglia.
In chapter 2 we investigated whether MTI changes could be detected in the 
GM, WM or both in patients suffering from MCI or AD. Using MTI we found 
evidence for structural brain changes in both GM and WM of patients with MCI 
and AD. Furthermore, these MTI changes were related to cognitive impairment 
as expressed by the mini mental state examination (MMSE) score. These findings 
imply that cerebral changes can be detected in both GM and WM even before 
patients are clinically demented. The finding of MTI changes in the GM might 
relate to classical AD type pathology, whereas WM MTI changes could indicate 
concomitant vascular pathology. 
The findings in chapter 2 raised the question of how the MTI changes found in 
this study are distributed over the GM and WM. This was investigated in chapter 
3. In this study we showed that brain damage, as detected by MTI, is widespread 
over the lobes in both AD and MCI patients whereas GM damage is more focally 
present in the temporal and frontal lobe of MCI patients. These findings are 
compatible with the knowledge that GM damage originates from the temporal 
lobe in AD. This interpretation is further supported by the observed independent 
association between temporal GM peak height and cognitive decline. MTI 
changes were found in all four lobes of the MCI patients investigated in this 
study and show the involvement of a diffuse process affecting the WM even 
before patients are clinically demented, a finding potentially explained by the 
presence of diffuse vascular pathology. 
Chapter 4 shows that the tCBF is strongly associated with parenchymal volume 
rather than age and, although much weaker, with the severity of WMHs. 
Although the association between tCBF and parenchyma volume seems 
straightforward, this finding has important implications for future studies. 
Volume flow measurements should be corrected for parenchymal volume rather 
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than age in all future studies in which flow measurements are being used as a 
diagnostic tool. In addition, studies including elderly patients or patients with 
a pathological increase of WMHs, such as diabetic type II subjects, should also 
correct their tCBF measurements for WMH volumes. 
Chapter 5 shows that hemodynamic conditions of the carotid and basilar 
arteries, as expressed in lower WSS parameters, are worse in both MCI and AD 
compared to controls. In addition, the WSS parameters were found to correlate 
strongly with cognition. Again, this study is additional evidence for an important 
role of vascular pathology in the development of AD.
In chapter 6, we found a high prevalence of microbleeds in a population of 
patients suffering from vascular disease or at high risk of developing this 
condition. Age, hypertension and WMH were the most important risk factors 
for microbleeds, especially when located in the cortico-subcortical junction and 
basal ganglia. Regarding the associations between the presence and location of 
microbleeds on the one hand and parameters of cognitive functioning on the 
other, chapter 7 shows that microbleeds located infratentorially are associated 
with impaired cognitive functioning in the aging population with increased 
vascular risk factors. This suggests that in elderly individuals microbleeds in the 
posterior fossa should be considered a sign of small vessel disease with potential 
functional consequences. 
The semi-quantative scale for scoring basal ganglia hypo-intensity on T2*-
weighted imaging presented in chapter 8 was associated with markers of 
neurodegeneration. This study showed that low signal intensity of the caudate 
nucleus T2*-weighted MR is a frequent finding which is associated with more 
cerebral atrophy, a higher load of WMH and a higher load of invisible changes 
in both cortical GM and NAWM non-demented elderly. Furthermore, hypo-
intensity limited to the globus pallidus and putamen was not associated with any 
of these parameters of neurodegeneration.
In chapter 9 we present a method for automated detection and classification of 
hypo-intense regions on T2-weighted MR images of the basal ganglia. In this 
chapter we not only show an association between basal ganglia hypo-intensity 
and cardiovascular risk factors but also with measures of cognitive functioning. 
From this we conclude that hypo-intensity of the basal ganglia on T2-weighted 
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MR is not only a radiological finding accompanying cerebral aging but also an 
independent marker of neurodegeneration.
Future studies
Multimodality approach
The last decades, extensive efforts have been made in the search for a non-invasive 
technique allowing the accurate diagnosis of dementia, especially Alzheimer’s 
disease. Technical advances in MR imaging and the increase in availability of MR 
have improved diagnostic reliability and have made MR imaging an integral part 
of the workup of patients with dementia. In the field of science the introduction 
of high field imaging (3T and up) and new techniques like spectroscopy, diffusion 
tensor imaging and magnetization transfer imaging have led to the discovery of 
new MRI biomarkers of AD and the refinement of existing ones. However, not 
only in imaging, but also in the fields of cellular and molecular biology, genetics, 
neuropsychology and nuclear medicine, large steps forward have been made. 
As these different fields of research provide complementary data on anatomy, 
physiology and biochemistry, future studies would benefit from a multi-modality 
approach. Data from neuroimaging studies combined with data on, for example, 
genetic risk and biomarker measures from other tissues like serum and CSF will 
provide insights in the pathological processes underlying age-related cognitive 
decline. 
Neuroimaging in disease-modification trails
Nevertheless, it should be kept in mind that the application of MRI in the 
diagnostic process is highly dependent on the development of an effective 
treatment of AD. Without the option of an effective intervention the usefulness 
of early diagnosis is limited. Currently a large number of treatments are under 
investigation. Concerning this quest for an effective treatment for AD MRI is 
increasingly included in these disease-modifying trials with atrophy measures, 
whether regional or global, as the main parameter. However, quantitative MR 
parameters have shown a strong correlation with cognitive functioning in 
multiple studies, including those included in this thesis. This advocates the 
inclusion of quantitative MR parameters in future studies. Furthermore, new 
MR parameters could be introduced as parameters. Future studies should 
explore these possibilities.
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Early detection
Detection of a pre-clinical phase of AD will become of paramount importance 
when effective interventions in the pathological cascade of AD become available. 
Early diagnosis would allow for early drug therapy and therefore improve 
clinical outcome. The definition of MCI as a prodromal state of AD in the field 
of neuropsychology has led to the recognition of a patient group with subtle 
cognitive deficits with a high probability for development of AD. This makes 
these subjects especially interesting for investigating the earliest changes found 
in AD. Quantitative MRI has shown promising results in this patient group but 
further research is needed in detecting pre-symptomatic patients who are at risk 
for dementia.
The broad spectrum of age-related changes of the brain
Although Alzheimer pathology received a large amount of attention in studies 
investigating cognitive decline, there is increasing awareness that age-related 
cognitive decline is a multi-factorial process in which different processes interact. 
A large amount of data exists on the effects of cerebrovascular pathology on 
age-related cognitive decline. Furthermore, changes in the neurotransmitter 
systems, environmental and lifestyle factors and endocrine function, have 
all been associated with cognitive decline. Our findings of new MRI markers 
being associated with cognitive decline are in line with this hypothesis. For 
example in this thesis we show that measures of basal ganglia hypo-intensity 
are independently associated with cognitive decline. This basal ganglia hypo-
intensity is found in various neurodegenerative diseases and therefore is an 
example that usual and pathological aging might share common pathways. 
Future imaging studies should aim to identify new pathways underlying age-
related cognitive decline and should try to identify imaging biomarkers of 
different disease mechanisms suggested by other fields of research. 
Longitudinal studies
Although quantitative MR parameters and new markers of cognitive decline 
have shown potential value in cross-sectional studies, less is known about their 
changes over time. Longitudinal studies are especially important in determining 
whether changes in these parameters correlate with or could predict cognitive 
decline. 
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Samenvatting en Conclusies
De algemene doelstelling van dit proefschrift is tweeledig: ten eerste 
onderzoeken we de toepasbaarheid van nieuwe (kwantitatieve) MRI-technieken 
in het onderzoek naar cerebrale veroudering en de ziekte van Alzheimer. Ten 
tweede bestuderen we de rol van cerebrale microbloedingen en ijzeraccumulatie 
in de basale kernen als mogelijke markers voor neurodegeneratie in deze twee 
processen. 
In hoofdstuk 2 onderzoeken we of er met behulp van Magnetization Transfer 
Imaging (MTI) afwijkingen in de grijze (GS) en/of witte stof (WS) van 
patiënten met Mild Cognitive Impairment (MCI) of de ziekte van Alzheimer 
(ZvA) kunnen worden aangetoond. Gebruikmakend van deze techniek vinden 
we structurele veranderingen in zowel de GS als WS van beide patiëntgroepen. 
Deze afwijkingen blijken gerelateerd aan de mate van cognitieve achteruitgang, 
weergegeven in een lagere Mini Mental State Examination (MMSE) score. Dit 
impliceert dat hersenafwijkingen kunnen worden aangetoond in zowel de GS 
als WS voordat patiënten klinisch dement zijn. De afwijkingen in de GS kunnen 
mogelijk worden toegeschreven aan ‘klassieke’ ZvA-pathologie, terwijl de WS-
afwijkingen mogelijk verklaard worden door de aanwezigheid van vasculaire 
pathologie.
De bevindingen in hoofdstuk 2 doen de vraag rijzen hoe de gevonden MTI-
veranderingen verdeeld zijn over de hersenen, hetgeen we onderzoeken in 
hoofdstuk 3. Structurele afwijkingen in de WS, zoals gekwantificeerd middels 
MTI, blijken verspreid te zijn over de frontale, temporale, pariëtale, en occipitale 
kwabben bij zowel MCI- als ZvA-patiënten. GS-schade blijkt bij MCI-patiënten, 
in vergelijking met ZvA-patiënten, echter meer focaal aanwezig in de temporale 
en frontale kwabben. Mogelijkerwijs reflecteren deze MTI-afwijkingen in 
de GS Alzheimerpathologie, waarvan bekend is dat deze het eerst gevonden 
wordt in de temporaalkwab. Deze suggestie wordt verder ondersteund door een 
onafhankelijke associatie tussen MTI-parameters (gemiddelde MTR en MTR-
piekhoogte) van de temporale GS en cognitie (MMSE). De aanwezigheid van 
vasculaire pathologie kan een verklaring zijn voor de meer diffuus aanwezige 
MTI-afwijkingen in de WS.
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In hoofdstuk 4 tonen we aan dat er een sterke associatie bestaat tussen de cerebrale 
bloedstroom, zoals gemeten met single slice fase contrast MR-angiografie, en het 
volume van het hersenparenchym. Ondanks dat deze associatie voor de hand 
ligt, heeft deze belangrijke gevolgen voor toekomstige studies. Alle toekomstige 
studies waarin cerebrale bloedstroommetingen worden verricht, zullen deze 
meting moeten corrigeren voor het cerebrale parenchymvolume in plaats van, 
zoals gebruikelijk in eerdere studies, de leeftijd van de patiënt. Ook vonden 
we een minder sterke associatie tussen de cerebrale bloedstroom en het witte 
stof laesievolume. Derhalve zullen studies in patiëntpopulaties met een hoge 
prevalentie van witte stof laesies, cerebrale bloedstroommetingen eveneens 
moeten corrigeren voor het witte stof laesievolume. 
Uit het onderzoek in hoofdstuk 5 blijkt dat de hemodynamische omstandigheden 
in de carotiden en de arteria basilaris, uitgedrukt in wall shear stress (WSS) 
parameters, van patiënten met MCI of de ZvA ongunstiger zijn dan die van een 
controle groep. Tevens blijken deze WSS parameters sterk te correleren met 
cognitie. Dit kan erop duiden dat vasculaire pathologie een rol speelt in het 
ontstaan van de ZvA.
In hoofdstuk 6 vinden we een hoge prevalentie van cerebrale microbloedingen 
in een populatie ouderen met vasculaire pathologie of een hoog risico hierop. 
Leeftijd, hypertensie en witte stof laesievolume blijken de belangrijkste 
risicofactoren voor microbloedingen, met name wanneer deze microbloedingen 
zich bevinden op de cortico-subcorticale overgang of in de basale kernen. 
Verbanden tussen de aanwezigheid van microbloedingen en cognitief 
functioneren onderzoeken we in hoofdstuk 7. Infratentorieel gelokaliseerde 
microbloedingen zijn geassocieerd met verminderde cognitie. Dit duidt erop dat 
microbloedingen in de fossa posterior een teken zijn van microvasculaire schade 
met mogelijk functionele consequenties. 
In hoofdstuk 8 presenteren we een semi-kwantitatieve schaal voor het graderen 
van basale kernen hypointensiteit. Met behulp van deze schaal tonen we aan dat 
lage signaalintensiteit van de nuclus caudatus op T* gewogen MRI-scans een 
veelvoorkomende bevinding is die geassocieerd is met cerebrale atrofie, witte stof 
laesie volume en afwijkingen in kwantitatieve MR-parameters. In tegenstelling 
tot de nucleus caudatus blijkt een lage signaalintensiteit van de globus pallidus 
en het putamen niet geassocieerd met ander afwijkingen op MRI. 
Samenvatting en Conclusies
129 
In hoofdstuk 9 introduceren we een nieuwe methode voor de detectie en 
classificatie van hypointense gebieden in de basale kernen op T2-gewogen 
MRI-sequenties. Deze hypodense gebieden zijn niet alleen geassocieerd met 
cardiovasculaire risicofactoren, maar blijken ook geassocieerd met cognitief 
functieverlies. Hypointensiteit van de basale kernen moet derhalve niet gezien 
worden als een normale bevinding in de oudere populatie maar als een indicator 
van neurodegeneratie. 
Toekomstig onderzoek
Disciplineoverstijgend onderzoek
Niet-invasieve methodes om gedurende het leven van de patiënt de diagnose 
dementie, en in het bijzonder de ZvA, te kunnen stellen, genieten al langere 
tijd een grote wetenschappelijke aandacht. Technische vooruitgang en de 
grotere toegankelijkheid tot MRI-systemen hebben geleid tot een toegenomen 
diagnostische betrouwbaarheid van MRI bij neurodegeneratieve ziekten. 
MRI maakt thans dan ook een integraal onderdeel uit van het diagnostisch 
traject bij patiënten die zich presenteren met cognitieve functiestoornissen. 
In de wetenschap heeft de introductie van hoge veld sterkte MRI (3T en 
hoger) en nieuwe MRI-technieken, zoals spectroscopie, diffusion tensor 
imaging and MTI, het inzicht in de verscheidenheid van neuroradiologische 
afwijkingen bij patiënten met de ZvA sterk doen toenemen. Echter niet alleen 
in de neuroradiologie maar ook in andere onderzoeksvelden, zoals cellulaire en 
moleculaire biologie, genetica, en neuropsychologie, is er progressie geboekt. In 
de toekomst zullen er grote stappen gemaakt worden met disciplineoverstijgend 
onderzoek, waarbij data uit neuroradiologische studies gecombineerd worden 
met data uit andere onderzoeksvelden. Dit zal leiden tot een dieper inzicht in de 
pathologische processen die ten grondslag liggen aan dementie in het algemeen 
en de ZvA in het bijzonder.
Neuroradiologie in klinisch onderzoek
Het belang van vroege diagnostiek van de ZvA is sterk afhankelijk van de 
ontwikkeling van een effectieve behandeling. Zonder de mogelijkheid van een 
(medicamenteuze) interventie is vroege diagnostiek van beperkte waarde. Op dit 
moment lopen er veel (klinische) onderzoeken naar potentiële behandelingen, 
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waarvan een aantal al in een vergevorderd stadium. In deze onderzoeken wordt er 
in toenemende mate gebruik gemaakt van regionale dan wel globale hersenatrofie, 
gekwantificeerd middels volumetrische MRI, als uitkomstparameter. Een groot 
aantal studies heeft echter al aangetoond dat er een sterke associatie bestaat 
tussen kwantitatieve MRI parameters en het cognitieve functioneren van 
patiënten met (beginnende) ZvA. Dit pleit ervoor dat ook deze parameters in 
de toekomst gebruikt kunnen worden voor het monitoren van ziekteprogressie 
in klinische studies.
Vroegdiagnostiek
Wanneer er een effectieve behandeling voor de ZvA beschikbaar komt, zal 
diagnostiek in een pre-klinische fase van de aandoening van groot belang worden. 
Deze vroege diagnostiek zal de mogelijkheid bieden om vroeg in het ziekteproces 
in te grijpen en de prognose waarschijnlijk positief te beïnvloeden. De definitie 
van MCI is een belangrijke ontwikkeling geweest in de neuropsychologie. De 
term MCI wordt gebruikt voor patiënten met geringe cognitieve klachten en 
een verhoogde kans op het ontwikkelen van de ZvA. Deze patiëntpopulatie is 
zeer interessant voor het bestuderen van de vroegste veranderingen in het brein 
bij de ZvA. Ondanks dat de resultaten van kwantitatieve MRI-technieken bij 
het aantonen van de vroegste veranderingen in het brein van MCI-patiënten 
veelbelovend zijn, zijn we nog niet in staat te bepalen welke patiënten wel en 
welke niet de ZvA ontwikkelen. Er is dan ook in de toekomst meer onderzoek 
nodig bij pre-symptomatische patiënten met een verhoogde kans op dementie 
om voorstadia van dementie te kunnen herkennen en diagnosticeren.
Het brede spectrum van leeftijdsgerelateerde afwijkingen in het brein
Ondanks dat er veel aandacht uitgaat naar de rol van Alzheimerpathologie in 
het ontstaan van dementie, zijn er steeds meer aanwijzingen dat cognitieve 
achteruitgang op hogere leeftijd een multifactoriële ontwikkeling is waarin 
meerdere processen een rol spelen. Zo is er reeds veel bekend over de invloed 
van vasculaire pathologie op het cognitief functioneren. Verder zijn er andere 
factoren, zoals veranderingen in het neurotransmitter systeem, omgevings- en 
lifestyle factoren en endocrinologische factoren, geassocieerd met cognitieve 
achteruitgang op hogere leeftijd. Toekomstige studies moeten zich toeleggen op 
het ontrafelen van de verschillende pathologische mechanismen die aan de basis 
liggen van het ontstaan van dementie. 
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Longitudinaal onderzoek 
Kwantitatieve MR parameters en markers van cognitieve achteruitgang 
hebben hun waarde in cross-sectionele studies aangetoond. Er is echter 
minder bekend over eventuele veranderingen van deze parameters na verloop 
van tijd. Toekomstige longitudinale studies zijn met name van belang voor 
het beantwoorden van de vragen of deze parameters correleren met cognitief 
functieverlies en of ze dit misschien kunnen voorspellen. 
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